СПОСОБЫ ПОЛУЧЕНИЯ АНТИБАКТЕРИАЛЬНЫХ КОНТАКТНЫХ ЛИНЗ

Группа изобретений относится к области медицины, в частности к офтальмологии, а именно: к антибактериальным линзам, содержащим металлы, а также способам их получения. Способ получения антибактериальной линзы, содержащей соль металла, включает стадии: (a) обработки отвержденной линзы предшественником соли, а также(b) обработки линзы, полученной на стадии (a), диспергирующей добавкой, выбранной из группы, состоящей из поливинилпирролидона, поливинилового спирта, глицерина и полиэтиленоксида, и металлсодержащим агентом, выбранным из группы, состоящей из тетрафторбората серебра, сульфата серебра, ацетата цинка, сульфата цинка, ацетата меди, сульфата меди, нитрат серебра, сульфида марганца, оксида цинка, сульфида цинка, сульфида меди, фосфата меди, нитрата серебра, сульфата серебра, йодата серебра, карбоната серебра, фосфата серебра, сульфида серебра, хлорида серебра, бромида серебра, йодида серебра и оксида серебра. Другой способ получения включает стадии (a) обработки отвержденной линзы металлсодержащим ...

УСТРОЙСТВО АППЛИКАЦИИ ЖИДКОСТИ И СПОСОБ

Группа изобретений относится к области медицины, а именно к подготовке пациентов к различным медицинским процедурам, например к хирургической операции, включающей в себя аппликацию раствора (или жидкости) для местного применения, например антисептического раствора, для дезинфекции целевого участка проведения медицинских процедур. Аппликаторное устройство для аппликации местного антисептика на кожу содержит ручку, имеющую проксимальный конец и дистальный конец; основание, соединенное с проксимальным концом ручки; гидрофильную пену, соединенную с основанием, и, по крайней мере, один абразивный слой, связанный с гидрофильной пеной. Гидрофильная пена предназначена для распределения местного антисептика на кожу. Абразивный слой и гидрофильная пена совместно пригодны для аппликации местного антисептика на кожу. Аппликаторная система в свою очередь содержит аппликаторное устройство, включающее в том числе гидрофильную пену, предназначенную для впитывания местного антисептика; и футляр, предназначенный ...

СПОСОБ ЛЕЧЕНИЯ ХРОНИЧЕСКОГО РЕЦИДИВИРУЮЩЕГО АФТОЗНОГО СТОМАТИТА

Изобретение относится к медицине, в частности к терапевтической стоматологии. Способ заключается в том, что на участок воспалённой слизистой оболочки полости рта однократно проводят аппликацию 5% водного раствора химотрипсина в течение 30 минут, а затем проводят курс аппликаций повиаргола - металл-полимерной композиции, содержащей высокодисперсное металлическое серебро и полимерный стабилизатор (поливинилпирролидон), разведённой в стерильной дистиллированной воде до концентрации 6%, в течение 30 минут 8 раз в сутки до полного исчезновения проявлений заболевания. 4 ил.

Лекарственное средство на основе синтетического сополимера винилпиридинового ряда для лечения тканевых гельминтозов

Изобретение относится к фармацевтической промышленности, а именно, к лекарственному средству в твёрдой лекарственной форме для лечения тканевых гельминтозов, выбранных из эхинококкоза и альвеококкоза. Предложенное средство содержит в качестве действующего вещества 35-65 мас.% сополимера N-винилпирролидона и 2-метил-5-винилпиридина формулы (I), где М мономерное звено формулы (II), n составляет 30-38 мол.% и средневязкостная молекулярная масса сополимера Мравна 15-28 кДа, а в качестве фармацевтически приемлемых вспомогательных веществ: а) 55-33,5 мас.% по меньшей мере одного вещества, используемого в качестве наполнителя и связующего, выбранного из лактозы моногидрата, микрокристаллической целлюлозы, двухосновного кальция фосфата дигидрата, изомальта, маннита, сахарозы, крахмала картофельного, крахмала кукурузного, декстранов, циклодекстранов, прежелатинизированного крахмала, и по меньшей мере одного связующего, выбранного из воды очищенной, поливинилпирролидона и гидроксипропилметилцеллюлозы ...

Противовирусная и иммуномодулирующая комбинация аминокапроновой кислоты и сополимера 2-метил-5-винилпиридина и N-винилпирролидона

Группа изобретений относится к области медицины, а именно к фармацевтике, и раскрывает комбинацию аминокапроновой кислоты и сополимера 2-метил-5-винилпиридина и N-винилпирролидона, а также способ профилактики гриппа, ОРВИ. Указанная комбинация характеризуется тем, что обладает противовирусным, иммуномодулирующим свойством, соотношение аминокапроновой кислоты и сополимера 2-метил-5-винилпиридина и N-винилпирролидона составляет 1:0,5 масс. %. Противовирусная и иммуномодулирующая комбинация может быть использована для профилактики вируса гриппа и ОРВИ. 2 н.п. ф-лы, 1 ил., 2 пр.

Полимерный материал медицинского назначения для эмболизации

Изобретение относится к области медицины и раскрывает материал медицинского и ветеринарного назначения, содержащий интерполимерный полиэлектролитный комплекс катионного полимера - полиалкилкарбоновой (полиакриловой или полиметакриловой) кислоты с анионным сополимером - N-винилпирролидона и 2-метил-5-винилпиридина или 4-винилпиридина или 2-винилпиридина. Эмболы из материала могут быть приготовлены предварительно в форме сферических и несферических частиц, вводимых в кровеносные сосуды в форме суспензии, или непосредственно внутри кровеносных сосудов (in situ) при совместном введении исходных компонентов. Дополнительно эмболы могут содержать химиотерапевтические и рентгеноконтрастные агенты. Материал характеризуется способностью к деструкции в результате воздействия электролитов и ферментативных систем организма человека и животных. Изобретение может быть использовано в качестве средства для эмболизации кровеносных сосудов с обратимым характером действия. 6 з.п. ф-лы, 2 табл., 4 пр., 1 ил ...

Препарат для профилактики и лечения воспалительных процессов у животных

Изобретение относится к ветеринарии и фармацевтической промышленности, а именно к препарату для профилактики и лечения воспалительных процессов (заболеваний) у животных, который включает (в мас.%): 0,15-0,25% мелоксикама в качестве нестероидного противовоспалительного средства, 7,5-12,5% этилметилгидроксипиридина сукцината, 5,0-10,0% левамизола основания, 2,5-4,5% поливинлпирролидона и воду для инъекций (остальное). Изобретение обеспечивает повышение противовоспалительного терапевтического эффекта при наличии антиоксидантного и иммуностимулирующего действия, а также снижение токсичности и частоты развития побочных эффектов. 7 пр., 7 ил.

Композиция для ингибирования активности β-глюкуронидазы

Изобретение относится к области фармацевтической промышленности. Предложен способ получения композиции для ингибирования активности β-глюкуронидазы, согласно которому готовят фосфатный буферный раствор сополимера винилпирролидона и виниламина (содержащего 90 молярных % звеньев винилпирролидона и 10 молярных % звеньев виниламина) при его концентрации в растворе 10-12 мас.%, готовят фосфатный буферный раствор смеси 1,4- и 3,6-лактонов D-сахарной кислоты с соотношением 40-60/60-40 мас.% при ее концентрации в растворе 21,5-24,0 мас.%, затем смешивают полученные растворы, далее объединенный раствор обрабатывают 25%-ным раствором гидроксида натрия до значения рН, равного 4,8-4,9, при 20-25°С и проводят лиофильную сушку указанного раствора. Изобретение обеспечивает повышение эффективности ингибирования β-глюкуронидазы с увеличением пролонгированного действия полученной композиции. 4 пр., 2 табл.

Способ получения препарата на основе альгината натрия и N-винилпирролидона, обогащенного активным йодом

Изобретение относится к области химико-фармацевтической промышленности, а именно к способу получения препарата на основе альгината натрия и N-винилпирролидона, обогащенного активным йодом. Способ получения препарата на основе альгината натрия и N-винилпирролидона, обогащенного активным йодом, включающий растворение йода в растворе йодистого калия в стерильной воде для инъекций, последующее добавление полисахарида, отличающийся тем, что растворяют 5-6 г йода в 30 г 10 мас.%-ного раствора йодида калия, приготовленного на стерильной воде для инъекций, после чего при постоянном перемешивании со скоростью 250 об/мин для получения вязкого раствора вносят 2-3 г, а для получения геля - 4-5 г привитого сополимера альгината натрия с соотношением остатков β-D-маннуроновой (М-звенья) и α-L-гулуроновой (G-звенья) кислот М-звенья/G-звенья=1,56 и вязкостью 1%-ного масс. водного раствора при 25°С, равной 4-12 cps, и N-винилпирролидона, с содержанием в сополимере привитых цепей N-винилпирролидона с молекулярной ...

Compound of tannin and crosslinked polyvinylpyrrolidone for the treatment of diarrhoeal disorders and wounds

Compound of tannin and crosslinked polyvinylpyrrolidone for the treatment of diarrhoeal disorders and weeping, infected and poorly healing wounds and the use thereof for the manufacture of pharmaceutical products.

ZUSAMMENSETZUNGEN UND IHRE VERWENDUNG ZUR VERHÜTUNG VON VERKLEBUNGEN ZWISCHEN KÖRPERGEWEBE

Synergistic binder composition, method for making same and tablets of an active and said binder having advantages hardness and friability

USE OF PVP-IOD LIPOSOMEN FOR THE TREATMENT OF ATOPI DERMATITIS

ANTISEPTIC COMPOSITIONS AND PROCEDURES

PROCEDURE FOR THE PRODUCTION OF A WUNDHEILMITTELS

PROCEDURE AND MEANS FOR THE PREVENTIVE TREATMENT OF SURGICAL ADHESIONS.

STABILIZED PVP-I SOLUTIONS

PROCEDURE FOR THE PRODUCTION OF A STURDY ANTIBIOTIC PREPARATION

Reduction of advanced glycation endproducts from bodily fluids

The invention concerns removing advanced glycation end products from a bodily fluid by contacting the bodily fluid with a sorbent.

Methods for closing suturable wounds by use of cyanoacrylate ester compositions comprising an antimicrobial agent

Ophthalmic compositions comprising povidone-iodine

A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post- LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection.and inflammation in the post-operative ophthalmic patient.

COMPOSITION FOR RESTORING DAMAGED SKIN

Enhanced production of clotting factors by cryoprecipitation

A COMBINATION FOR THE TREATMENT OF OSTEOARTHRITIS

The present invention relates to the use of a combination of glycine, proline, and optionally a natural or synthetic viscosity-controlling polymer, and/or lysine and/or leucine, to prepare a composition for the treatment of osteoarthritis.

BASE FOR OPHTHALMOLOGICAL MEDICINAL PREPARATIONS AND AN OPHTHALMOLOGICAL MEDICINAL FILM

A base for ophthalmological medicinal preparations consists of at least one polymer selected from a homopolymer of an amide of acrylic acid having a molecular weight from 30,000 to 1,000,000, and a copolymer of an amide of acrylic acid with unsaturated compounds from the group consisting of N-vinylpyrrol-idone, ethyl acrylate, butyl acrylate, N-vinylcaprolactam, vinyl acetate, the molecular weight of the copolymer being from 20,000 to 500,000, and containing from 10 to 90 per cent acrylamide links and an active principle selected from the group consisting of 3-ethyl-4(1-methyl-5-imidazolyl)-tetrahydrofuran-2-one, atropine, 3-methoxy-6-sulphanilamindopyridazine, .beta.-dimethylaminoethyl-p-butylaminobenzoate, neamine and 5-iodo-2-desoxyuridine. The ophthalmological medicinal film is an oblong plate, 6 - 9 mm long, 3 - 5 mm wide and 0.2 - 0.6 mm thick consisting of at least one polymer selected from a homopolymer of an amide of acrylic acid having a molecular weight from 30,000 to 1,000,000 ...

FLUID APPLICATION DEVICE AND METHOD

PHARMACEUTICAL FORMULATIONS THAT FORM GEL IN SITU

The present invention provides aqueous formulations containing an anti-infection agent, a biocompatible polysaccharide, an osmotic pressure regulator, a pH regulator, and water, wherein a gel containing the therapeutic agent is formed in situ upon instillation of the formulations onto the skin and a body cavity of a subject. The formulations of this invention are useful for treating infectious diseases of skin or a body cavity (e.g., eye, nose, or vagina) of a subject.

POLYMERIC DRUG AGENTS FOR THE TREATMENT OF FIBROTIC DISORDERS

Agents and methods for treatment of adhesions and fibrotic diseases, through the release of drugs that retard or inhibit fibrotic tissue production. A method for releasing fibrotic tissue-inhibiting agents from a polymer is provided. The polymer/drug combination can be applied directly to affected site as a liquid, gel, or paste. Alternatively, the polymer/drug combination can be injected ( intravenous, intraperitoneal, or subcutaneous) in an appropriate vehicle.

TOPICAL ANTISEPTIC SYSTEM

Novel antimicrobial compositions and kits thereof containing these antimicrobial compositions, methods of manufacture and methods of use thereof are disclosed. The novel aqueous transdermal or topical delivery systems are useful, inter alia, for treatment of various microbial infections, including for use on tissue infections, particularly skin antisepsis and/or nasal mucosal tissue antisepsis to a mammalian host in need thereof.

NOVEL IODOPHOR COMPOSITION AND METHODS OF USE

Described are stable topical formulations useful in the treatment of viral wart infection, demodex infection and bacterial infection of the skin, and genitalia and the method of treating viral wart infection, demodex infection and bacterial infection of the skin, and genitalia with said compositions.

STABLE POVIDONE-IODINE COMPOSITIONS

Disclosed herein are PVP-I-containing compositions, as well as methods of making such compositions, which provide reliable stability for PVP-I preparations, including preparations comprising PVP-I and one or more additional components.

OPHTHALMIC FORMULATIONS

There is provided inter alia a germicidal aqueous formulation, suitable for use in the eye, which has a pH of from 4.0 to 6.5 and which comprises 4.0 to 7.5% w/w of povidone-iodine and a viscosity increasing agent, the formulation buffered with a buffer concentration of 25 mM to 75 mM.

SEMI-PASTE ORAL PREPARATIONS

A semi-paste oral preparation comprises, as effective ingredients, at least 0.1 to 20% by weight of povidone-iodine based on the total weight of the preparation, and 0 to 50 parts by weight of potassium iodide and 1 to 300 parts by weight of a sugar alcohol of an oligosaccharide as a base and stabilizer, the parts by weight being based on one part by weight of the povidone-iodine. This semi-paste oral preparation has a modest viscosity, good taste and good stability upon storage for a long time.

USE OF PROTEIN KINASE C INHIBITORS TO ENHANCE THE CLINICAL EFFICACY OF ONCOLYTIC AGENTS AND RADIATION THERAPY

A method for treating neoplasms is disclosed, particularly using the .beta.isozyme selective PKC inhibitor, (S)-3,4-¢N,N'-1,1'-((2''-ethoxy)-3'''(O)-4'''- (N,N-dimethylamino)-butane)-bis-(3,3'-indolyl)!-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.

Verfahren zur Herstellung eines Jodpräparates.

Verfahren zur Herstellung eines Jodpräparates.

Verfahren zur Herstellung von stabilen, für die parenterale, perorale und lokale Verabreichung geeigneten wässrigen Oxytetracyclinlösungen

[...] DE [...] DE [...] DE [...] D' [...][...].

Eye insert for the generation of artificial tears

WUNDHEILMITTEL TO THE COVERAGE OF WOUNDS AND BURNS.

Use of a compound for the preparation of compositions capable of reducing variations in the waist size and the effect of constipation associated the previous other agents.

ТВЕРДАЯ ФОРМА ЦЕЛЕКОКСИБА, ИМЕЮЩЕГО ПОВЫШЕННУЮ БИОДОСТУПНОСТЬ

... 1. Аморфный целекоксиб. 2. Лекарственное вещество целекоксиб, в котором целекоксиб присутствует, по меньшей мере, в обнаруживаемом количестве, в виде аморфного целекоксиба. 3. Лекарственное вещество по п.2, в котором аморфный целекоксиб присутствует в количестве, составляющем приблизительно от 10 до 100 маc.% от всего целекоксиба. 4. Лекарственное вещество по п.2, включающее, по существу, чистофазный аморфный целекоксиб. 5. Композит, ингибирующий кристаллизацию целекоксиба, включающий частицы аморфного целекоксиба или лекарственного вещества целекоксиба по любому из пп.2-4 в ассоциации с одним или несколькими ингибиторами кристаллизации в количестве, эффективном для снижения превращения аморфного целекоксиба в кристаллический целекоксиб. 6. Композит по п.5, в котором ингибитором кристаллизации является полимер. 7. Композит по п.6, в котором полимер выбирают из поливинилпирролидона и гидроксипропилметилцеллюлозы. 8. Композит по п.6, в котором полимером является поливинилпирролидон. 9. Композит ...

ANTISEPTIC COMPOSITION COMPRISING POLYVINYLPYRROLIDONE AND UNITHIOL AND USE OF THE COMPOSITION

ANTISEPTIC COMPOSITION COMPRISING POLYVINYLPYRROLIDONE AND UNITHIOL AND USE OF THE COMPOSITION

ANTISEPTIC COMPOSITION, CONTAINING POLYVINYLPYRROLIDONE AND UNITHIOL, AND APPLICATION OF SAID COMPOSITION

Solid composition comprising iodine agent and sodium chloride having improved water solubility, and antiviral and antimicrobial composition for eye, oral cavity, nasal cavity or inhalation containing aqueous solution thereof

Medicine for relieving spasm and pain and preparation process thereof

The present invention relates to a medicine for relieving spasm and pain and its preparation method. It utilizes medicine active matter glycyrrhetinic acid extracted from licorice and paenoiflorin extracted from peony root, and uses their respective effective amount and medicinal carrier and/or excpient to make them into the modern medicine with small volume, easy storage, convenient administration and therapeutic effect identical to that of peony licorice decoction. Said medicine also has no toxic effect.

NEW DERMATOLOGICAL COMPOSITIONS AND/OR COSMETOLOGIQUES HYDRATING ETANTI-IRRITANTES

INSERT OPHT

HEALING PHARMACEUTICAL COMPOSITION CONTAINING AN AGENT ANTIFONGIQUE/ANTIBACTERIEN AND SUGAR AND ITS APPLICATIONS

PROCESS FOR THE PREPARATION OF CYCLOSPORIN HAS AN EYE DROP

Ant-ageing lung-protecting compns

Composition, useful e.g. to protect skin against toxic chemical agents of organophosphate compounds, comprises e.g. N-vinyl 2-pyrrolidone homopolymer, and 2-methacryloyloxyethyl phosphorylcholine/alkyl methacrylate- copolymer

L'invention se rapporte au domaine des nécessités de la vie et en particulier au domaine de la dermocosmétique. Elle concerne spécifiquement des compositions dermatologiques ou cosmétiques associant pr un effet barrière épidermique un homopolymère de N-vinyl 2-pyrolidone ou un copolymère de vinylpyrrolidone / triacontène ou de vinylpyrrolidone / eicosène avec un copolymère de 2-méthacryloyloxyéthyl phosphorylcholine / méthacrylate d'alkyle ou un copolymère de 2-méthacryloyloxy éthylphosphorylcholine / chlorure de 2-hydroxy 3-méthacryloyl oxypropyle triméthylammonium, dans une composition topique dermoprotectrice. Utilisation des compositions dermatologiques et / ou cosmétiques pour assurer la protection cutanée contre les agents chimiques toxiques de la famille des composés organophosphorés et contre les agents chimiques de la famille des ypérites.

OPHTHALMIC COMPOSITIONS COMPRISING POVIDONE-IODINE

Ophthalmic compositions comprising povidone-iodine

A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient.

EXTERNAL AGENT FOR TREATING WOUND

... [PROBLEMS] To provide a novel and less toxic external agent for treating wound which has a sufficient effect of promoting healing of intractable diseases such as erosion, bedsore and skin ulcer while preventing cicatrization and lessening iodine accumulation on the wound face. [MEANS FOR SOLVING PROBLEMS] An external agent for treating would which contains an oily base and iodine characterized by being substantially free from sucrose. Using this external agent for treating would, infection from the wound face can be prevented due to the sufficient bactericidal effect of iodine and healing of the would can be promoted while preventing cicatrization and lessening iodine accumulation on the wound face by the effect of maintaining the humidity on the wound face at an appropriate level due to the moisturizing effect of the oily base.

METHODS FOR CLOSING SUTURABLE WOUNDS BY USE OF CYANOACRYLATE ESTER COMPOSITIONS COMPRISING AN ANTIMICROBIAL AGENT

Antimicrobial cyanoacrylate compositions are applied to suturable wound surfaces to close the wound surface.

PROCESS FOR PREPARING PVP-IODINE PRODUCT

A proces for preparing a water-insoluble or water-soluble PVP-iodine product which comprises intimately mixing water-insoluble PVP or water-soluble PVP having a K-value of 10-20, about 10 to 20 % by weight of iodine powder and about 0.05 to 1 % by weight of isopropanol, heating the reaction mixture at a mixing temperature of room temperature to about 30-60 °C for about 0.5 to 6 hours, and heating the mixture at a reaction temperature of about 65 to 98 °C for about 10-24 hours, generally at least 18 hours, to form a stable, uniform, free-flowing powder.

Parasiticidal composition

A parasiticidal composition comprising, as an active ingredient, at least one bioadhesive polymer and salts thereof together with at least one physiologically acceptable carrier.

Ocular tissue regeneration inducer

The invention relates to an ocular tissue regeneration inducer which comprises, as an active ingredient, a hydrophilic polymer mainly composed of alkylene glycol units or vinyl monomeric units having a nondissociating hydrophilic group. The composition can induce the regeneration of ocular tissues such as the cornea, the crystalline lens, and the vitreous body.

Pharmaceutical preparation for the oral administration of dihydropyridines

Pharmaceutical preparations for the oral administration of dihydropyridines in beverage form are described. These preparations are characterized in that they contain a coprecipitate of essentially amorphous dihydropyridine with a suitable pharmacologically acceptable polymer. The corresponding preparation processes are also described.

Ocular implants and methods for their manufacture

APPLICATOR FOR MEDICAL-USE LIQUIDS

An applicator for medical-use liquids includes a handle having a hollow cylindrical member, a container incorporated in the cylindrical member, and a cleaving member of the container; and an applying section having an attachment plate of an application pad (integrally) fixed to a lower end of the cylindrical member to be an inclined cross section and the application pad fixed to the attachment plate. The attachment plate has a bank section formed thick at a peripheral edge, a base bottom section formed as a recess in a center, an inclined outflow hole opened inclinedly with respect to the base bottom section near the base bottom section center such that the solution flows out toward an attachment plate distal end direction, and a weir provided in an arcuate or crescent shape. A flow of the solution flowed out from the inclined outflow hole is reversed to flow backward by the weir.

Composition using cross-linked hyaluronic acid for topical cosmetic and therapeutic applications

Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin.

NON-IRRITATING OPHTHALMIC POVIDONE-IODINE COMPOSITIONS

Antimicrobial composition comprising a vinyyl pyrrolidinon derivative and a carbapenem antibiotic or a beta-lactamase inhibitor

КОМБИНАЦИЯ ДЛЯ ЛЕЧЕНИЯ ОСТЕОАРТРИТА

Настоящее изобретение относится к ортопедии и представляет собой состав для внутрисуставного введения с целью лечения остеоартрита, включающий глицин, пролин, лизин, лейцин и регулирующий вязкость полимер. Осуществление изобретения обеспечивает расширение арсенала средств для лечения остеоартрита, обеспечивая снижение тяжести заболевания и болевых симптомов, а также увеличение средней толщины хряща. 6 з.п. ф-лы, 3 табл.

ОФТАЛЬМОЛОГИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ПОВИДОН-ИОД

Группа изобретений относится к области клинической фармакологии, а именно к офтальмофармакологии, и предназначена для офтальмологического применения стабильной композиции, содержащей повидон-йод. Офтальмологическая композиция содержит водную фазу, масляную фазу и повидон-йод (PVP-I) в концентрации 0,2-1,0% (масса/масса). Указанная масляная фаза состоит из триглицеридов со средней длиной углеродной цепи и составляет менее 3% от суммарной массы композиции. Указанная композиция может входить в состав фармацевтического препарата для терапевтического применения в офтальмологии. Также обеспечивается способ лечения офтальмологических патологических состояний, включающий введение указанной композиции. Использование группы изобретений обеспечивает физико-химическую стабильность и сохранение высокого содержания свободного молекулярного йода, а также хорошую переносимость пациентами при лечении заболеваний глаз. 3 н. и 10 з.п. ф-лы, 1 ил., 10 табл., 17 пр.

ГИДРОФИЛЬНАЯ МАЗЬ ДЛЯ ЛЕЧЕНИЯ ИНФИЦИРОВАННЫХ РАН

Изобретение относится к фармацевтической промышленности, а именно к гидрофильной мази для лечения инфицированных ран. Гидрофильная мазь для лечения инфицированных ран, содержащая повиаргол, метилурацил, метилцеллюлозу, воду, взятые при определенном соотношении компонентов. Вышеописанная мазь позволяет сократить период воспалительного процесса, ускорить эпителизацию и нетоксична при использовании. 1 табл., 8 пр.

Способ профилактики респираторных вирусных инфекций (гриппа)

Изобретение относится к медицине, а именно к профилактике инфекционных болезней и может быть использовано для профилактики гриппозной инфекции. Способ включает интраназальное введение в физиологическом растворе сополимера винилфосфоновой кислоты с 4-акрилоилморфолином (ВФК-4-АМ), содержащего 35-70 мол.% винилфосфоновой кислоты, с молекулярной массой (20-70)⋅103, при концентрации сополимера 300 мкг/мл в объеме раствора 30 мкл. Использование изобретения позволяет проводить неспецифическую профилактику гриппозной инфекции при местном применении. 2 ил., 2 табл., 2 пр.

НОВЫЕ ПРОИЗВОДНЫЕ ВАНАДИЯ, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКОЙ АКТИВНОСТЬЮ

Изобретение относится к новому соединению ванадия, представляющему собой полимерное производное ванадия общей формулы (I):(V=O)-(R)m (I),где V=O представляет собой ион ванадила VO,R – полимерный остаток, представляющий собой поливинилпирролидон формулы,m – целое число, принимающее значение от 1 до 2, n – целое число, принимающее значение от 100 до 350. Также предложены применение соединения ванадия, фармацевтическая композиция и ее применение. Данные соединения обладают гипогликемической активностью и могут быть использованы для лечения диабета 1 или 2 типа. 4 н. и 8 з.п. ф-лы, 5 ил., 3 пр.

Способ лечения больных сальмонеллёзом телят

Изобретение относится к области ветеринарии и представляет собой способ лечения больных сальмонеллезом телят, включающий пероральное введение препарата диастоп в дозе 10 мл/кг массы тела два раза в сутки в течение 3 дней и дополнительно внутримышечно вводят препарат биферон-Б в дозе 0,1 мл/кг массы тела один раз в сутки в течение 3 дней. Использование способа позволяет повысить эффективность лечения и сократить сроки лечения сальмонеллеза у телят. 3 табл., 3 пр.

ОФТАЛЬМОЛОГИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ПОВИДОН-ИОД

Способ изготовления антимикробной композиции в виде мази для нанесения на рану

Изобретение относится к медицине, а именно к способам изготовления антимикробных композиций для нанесения на раны. Целью изобретения является повышение атравматичности композиции. Способ заключается в том, что носитель (мазевую основу) в количестве 10-35% массы композиции смешивают с антимикробным агентом - комплексом поливинилпирроли- дона с йодом и сахарами, взятыми в соотношении 1:(10-80). При зтом в качестве Сахаров используют сахарозу, глюкозу, де- кс.трозу, фруктозу, мед, мелассу или их смеси. 2 з.п.ф-лы.

Stabile,waessrige Oxytetracyclinloesungen und Verfahren zu ihrer Herstellung

Polyvinylpyrrolidone-contg medicament - for treating ulcers and burns

The medicament has a favourable effect on skin regeneration in cases of ulceration (e.g. ulcus cruris varicosum) and of burns. It is also useful in the treatment of all wounds where there is deficient keratinisation.

ZUSAMMENSETZUNG ZUR BEHANDLUNG PROGRESSIVER MYOPIE.

Parasiticidal composition

PROCEDURE FOR THE PRODUCTION OF PVP-H202-PRODUKTEN

ANTIMICROBIAL COMPOSITIONS WHICH VINYLPYRROLIDINON CEPHALOSPORIN DERIVATIVES AND A CARBAPENEMANTIBIOTIKUM OR BETA LACTAMASEINHIBITOR ENTHATEN

PROPELLANT PREPARATION FOR THE HEALING OF INJURING SKIN

PROCEDURE FOR THE PRODUCTION OF A WUNDHEILMITTELS

VERFAHREN ZUR HERSTELLUNG EINES STABILEN ANTIBIOTISCHEN PRAPARATES

VERFAHREN ZUR HERSTELLUNG EINES WUNDHEILMITTELS

NEW COMPOSITION AGAINST XEROSTOMIE

COMPOSITIONS AND YOUR USE FOR PREVENTING OF GLUINGS BETWEEN BODY FABRICS

Methods and compositions to prevent formation of adhesions in biological tissues

ANTI-TUMOUR POLYMER COMPOSITIONS

Antimicrobial alcohol gel pre-operative skin-preparation delivery systems

Ophthalmic compositions comprising pheniramine and povidone

Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome

Increased solubility flavanolignan preparations

Stable antiseptic compositions and methods

Provided are methods of improving the stability of antiseptic compositions that include elemental iodine and certain hydroxycarboxylic acids, as well as stable, ready to use antiseptic compositions suitable for use in the nose and anterior nares.

Antiseptic composition comprising polyvinylpyrrolidone and unithiol and use of the composition

... The invention relates to novel polymer-based antiseptic compositions for treating wounds and/or for use in surgical operations, which form a film on the wound surface and have antiseptic, anesthetic and antitoxic effects. The compositions according to the invention comprise polyvinylpyrrolidone with a weight average molecular weight in the range of 1,000,000 to 3,000,000 Da, one or more antiseptics, unithiol, dimethylsulfoxide, and one or more anesthetics, preferably local anesthetics. In addition, the present invention relates to use of the compositions according to the invention in a wound treatment, as well as methods for treating wounds using the compositions according to the invention comprising the step of applying the composition according to the invention to a wound surface.

Compositions and methods for treatment of skin infections

A pharmaceutical composition for treating skin infections is described herein. A method using a pharmaceutical composition for treating skin infections is described herein. A pharmaceutical composition for treating skin infections may comprise, in 100 parts of the composition, 1 99 parts of a pharmaceutically acceptable excipient; 99 1 parts of a keratolytic; 99 1 parts ethyl pyruvate; and 99 1 parts povidone iodine. A method for treating skin infections may comprise topical application of a composition to an infected skin cell for a treatment period.

AGENTS HAVING A TUMOUR-INHIBITING ACTION AND THEIR USE

METHOD OF CLEANSING CONTAMINATED WOUNDS AND SURGICAL SCRUB SOLUTIONS FOR SAME

Polymers for reversing heparin-based anticoagulation

Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.

combination for the treatment of osteoarthritis

The present invention relates to the use of a combination of glycine, proline, and optionally a natural or synthetic viscosity-controlling polymer, and/or lysine and/or leucine, to prepare a composition for the treatment of osteoarthritis.

OTIC COMPOSITIONS FOR THE TREATMENT OF INFECTIONS OF THE INTERNAL AND EXTERNAL EAR IN MAMMALS

Disclosed herein compositions including povidone-iodine (PVP-I) useful in the treatment of acute and chronic bacterial, viral and fungal infections of the internal, middle and external ear of mammals, including humans. 1. A method of treating a mammal having an otic infection , the method comprising contacting the ear of the mammal with a composition comprising:a. povidone iodine (PVP-I) at a concentration of 0.01%-5.0%; andb. a steroid at a concentration of 0.01%-2.0%.2. The method of claim 1 , wherein the otic condition is at least one member selected from the group consisting of bacterial otitis externa claim 1 , malignant otitis claim 1 , fungal otitis externa claim 1 , otomycosis claim 1 , otitis media claim 1 , and otitis interna.3. The method of claim 1 , wherein the steroid is selected from the group consisting of a dexamethasone claim 1 , a fluromethalone claim 1 , a lotoprendol claim 1 , a medrysone claim 1 , a prednisolone claim 1 , a difluprednate claim 1 , a rimexolone claim 1 , and a hydrocortisone.4. The method of claim 1 , wherein the steroid is dexamethasone or a salt thereof.5. The method of claim 1 , wherein the composition is contacted to the ear in the form of an ear drop or a zinc acetate composition.6. The method of claim 1 , wherein the PVP-I is present at a concentration of 1.0%-3.0%.7. The method of claim 1 , wherein the PVP-I is present at a concentration of 2.0%.8. The method of claim 1 , wherein the steroid is present at a concentration of 0.05%-0.1%.9. The method of claim 1 , wherein the steroid is present at a concentration of 0.1%.10. A method of treating a mammal having an otic infection claim 1 , the method comprising contacting the ear of the mammal with a composition comprising:a. PVP-I at a concentration of about 2.0%; andb. dexamethasone at a concentration of about 0.1% This application is a continuation of U.S. patent application Ser. No. 13/234,978, filed on Sep. 16, 2011, which is a continuation of U.S. patent application Ser ...

STABLE ANTISEPTIC COMPOSITIONS AND METHODS

Abstract: Provided are methods of improving the stability of antiseptic compositions that include elemental iodine and certain hydroxycarboxylic acids, as well as stable, ready to use antiseptic compositions suitable for use in the nose and anterior nares. 1. A tissue antiseptic composition comprising:an antimicrobial agent which is an iodophor, wherein the iodophor is povidone-iodine, wherein the antimicrobial agent is present in a sufficient concentration to provide an available iodine concentration of 0.1 wt-% to 2 wt-%;a hydroxycarboxylic acid present at a concentration of at least 2.5 wt-%;an amine oxide; andan iodide salt present in at least a concentration of 2.0 wt-% and at an amount of no greater than 10 wt-%, wherein the composition is ready to use.23-. (canceled)4. The tissue antiseptic composition of which exhibits a decrease in available iodine of no greater than 5% wt/wt when stored at 40° C. for about 6 months.5. The tissue antiseptic composition of claim 1 , wherein the hydroxycarboxylic acid is present in an amount greater than 5 wt-%.6. The tissue antiseptic composition of claim 1 , wherein the amine oxide is present in a concentration of 0.25 wt-% to 1.5 wt-%.79-. (canceled)10. The tissue antiseptic composition of claim 1 , further comprising a monosaccharide claim 1 , a sugar alcohol claim 1 , or a combination thereof claim 1 , wherein the monosaccharide claim 1 , sugar alcohol claim 1 , or combination thereof is present at a concentration of greater than 5% wt/wt.11. The tissue antiseptic composition of claim 10 , wherein the composition comprises xylitol.12. (canceled)13. The tissue antiseptic composition of claims 1 , further comprising a surfactant; wherein the surfactant comprises an anionic surfactant claims 1 , an amphoteric surfactant claims 1 , a nonionic surfactant claims 1 , a zwitterionic surfactant claims 1 , or a combination thereof; wherein the anionic surfactant comprises a phosphate claims 1 , phosphonate claims 1 , sulfate ...

HYDROGEL CO-POLYMER COMPOSITION AND ITS USES, FOR EXAMPLE AS A WOUND DRESSING

The present invention provides a hydrogel composition, preferably for the treatment of wounds, comprising a hydrophilic co-polymer carrying multiple pendant anionic groups, wherein the polymer is derived from a first monomer and a second monomer, wherein both monomers have an octanol:water partition coefficient Log P value of less than 0, and, the Log P value of the first monomer is greater (more positive) than the second monomer. The difference between the Log P value for the two monomers is preferably less than 2. The weight ratio (w/w) of the first monomer/second monomer in the hydrogel composition is preferably equal to or more than about 1. The pendant anionic groups may be sulphonyl groups, e.g. sulphonic acid groups or salts thereof. The anionic group in both first and second monomers may be in salt form and the counterion for both monomers is preferably the same. 1. A hydrogel composition for the treatment of wounds , comprising a hydrophilic co-polymer carrying multiple pendant anionic groups , wherein the polymer is derived from a first monomer and a second monomer , wherein both monomers have an octanol:water partition coefficient Log P value of less than 0 , wherein the first monomer has a Log P value greater (more positive) than the second monomer and the weight ratio (w/w) of the first monomer/second monomer in the hydrogel composition is equal to or more than about 1.2. A hydrogel composition according to claim 1 , wherein both the first and second monomers comprise a pedant anionic group in acid or salt form and claim 1 , either (i) the anionic group in both first and second monomers is in acidic form or (ii) the anionic group in both first and second monomers is in salt form and the counterion for both monomers is the same.3. A hydrogel composition for the treatment of wounds claim 1 , comprising a hydrophilic copolymer formed from a first monomer and a second monomer claim 1 , wherein the first monomer comprises an acrylic acid ester sulphonic acid ...

Peg based hydrogel for peripheral nerve injury applications and compositions and method of use of synthetic hydrogel sealants

Hydrogels that may be used for treating peripheral nerves and related methods are provided. Synthetic hydrogel sealants, methods of forming synthetic hydrogel sealants, and the use of synthetic hydrogel sealants are provided.

PTEROSTILBENE AND PVP GRAPE JUICE EXTRACT COMBINATION FOR TREATMENT OF METABOLIC, VASCULAR, AND NEURODEGENERATIVE DISORDERS

A pharmaceutical composition is provided comprising a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a polyphenolic-PVP extract of grape juice, and a pharmaceutically acceptable carrier. The embodiments of the pharmaceutical compositions can have lipid lowering properties, or alternatively can have properties that can treat oxidative stress, by decreasing inflammation or inflammatory processes contributing to neurodegenerative diseases. A method of lowering lipid levels in an individual is also provided, comprising administering to the individual in need of such treatment a pharmaceutical composition including a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a polyphenolic-PVP extract of grape juice, and a pharmaceutically acceptable carrier, wherein lipid levels are decreased. 1. A lipid-lowering composition comprising a therapeutically effective amount of pterostilbene , a therapeutically effective amount of a polyphenolic-PVP extract of grape juice , and a pharmaceutically acceptable carrier.2. The lipid-lowering composition of claim 1 , wherein pterostilbene is present in an amount from about 10 mg to about 500 mg claim 1 , and the polyphenolic-PVP extract of grape juice is present in an amount from about 100 mg to about 300 mg.3. The lipid-lowering composition of claim 1 , wherein pterostilbene is present in an amount from about 25 mg to about 500 mg claim 1 , and the polyphenolic-PVP extract of grape juice is present in an amount from about 100 mg to about 300 mg.4. The lipid-lowering composition of claim 1 , wherein pterostilbene is present in an amount from about 50 mg to about 150 mg.5. An antiinflammatory composition comprising a therapeutically effective amount of pterostilbene claim 1 , a therapeutically effective amount of a polyphenolic-PVP extract of grape juice claim 1 , and a pharmaceutically acceptable carrier.6. The antiinflammatory composition of claim 5 , wherein ...

NON-IRRITATING OPTHALMIC POVIDONE-IODINE COMPOSITIONS

Disclosed are compositions and methods comprising povidone-iodine and a cooling-effective amount of a chemical agent. The compositions are useful to relieve mild ocular irritation, enhance ocular comfort, and to provide a refreshing effect and improved sensation, when the povidone-iodine solution is applied to the eye. 1. A ophthalmic preparation comprising:a. povidone-iodine at a concentration from about 0.1% to about 2.5% said ophthalmic preparation,b. at least one member selected from the group consisting of a lubricant and a cooling agent, at a concentration which is not irritating to the eye; andc. optionally, one or more of the members selected from the group consisting of camphor, borneol, a lubricant, an emollient, a steroidal anti-inflammatory compound, and a non-steroidal anti-inflammatory compound.2. The ophthalmic preparation of claim 1 , wherein the PVP-I is present at a concentration selected from the group consisting of 0.2% to 2.0% claim 1 , 0.3% to 1.5% claim 1 , 0.36% to 1.0% claim 1 , and 0.4% to 0.75%.3. The ophthalmic preparation of claim 1 , wherein the PVP-I is present at a concentration selected from the group consisting of about 0.05% claim 1 , about 0.1% claim 1 , about 0.2% claim 1 , about 0.3% claim 1 , about 0.4% claim 1 , about 0.5% claim 1 , about 0.6% claim 1 , about 0.7% claim 1 , about 0.8% claim 1 , about 0.9% and about 1.0%.4. The ophthalmic preparation of claim 1 , wherein said non-steroidal anti-inflammatory compound is selected from the group consisting of ketotifen fumarate claim 1 , diclofenac sodium claim 1 , nepafenac claim 1 , bromfenac claim 1 , flurbiprofen sodium claim 1 , suprofen claim 1 , celecoxib claim 1 , naproxen claim 1 , rofecoxib claim 1 , and any combination thereof.5. The ophthalmic preparation of claim 1 , wherein said steroidal anti-inflammatory compound is selected from the group consisting of dexamethasone claim 1 , dexamethasone alcohol claim 1 , dexamethasone sodium phosphate claim 1 , fluromethalone ...

NON-ANTICOAGULANT SULFATED OR SULFONATED SYNTHETIC POLYMERS

The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro. 1. A pharmaceutical composition comprising a therapeutically effective amount of a non-anticoagulant , non-saccharide , sulfonated/sulfated synthetic polymer (NASSP); and a pharmaceutically acceptable excipient.4. A unit dosage formulation for use in a method for treating a subject in need of enhanced Hood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant claim 1 , non-saccharide sulfonated/sulfated polymer to the subject claim 1 , the unit dosage formulation comprising the pharmaceutical composition according to in a therapeutically effective amount.5. The unit dosage formulation according to claim 4 , comprising from about 0.5 mg to about 1000 mg of the non-anticoagulant claim 4 , non-saccharide sulfonated/sulfated polymer.6. The unit dosage formulation according to wherein the polymer is in an amount sufficient to provide a dosage from about 0.01 mg/kg to about 100 mg/kg.7. The unit dosage formulation according to claim 4 , wherein the polymer is present in the formulation in an amount sufficient to enhance blood coagulation in a subject to whom the unit dosage formulation is administered.8. The unit dosage formulation according to claim 4 , wherein the unit dosage formulation is an oral unit dosage formulation.9. A method for treating a subject in need of enhanced blood coagulation claim 1 , comprising administering a therapeutically effective amount of the pharmaceutical composition according to .10. The method according to claim 9 , wherein the polymer is administered to the subject at a dosage of about 0.01 mg/kg ...

Functionalized Water-Soluble Polyphosphazenes and Uses Thereof as Modifiers of Biological Agents

A polyphosphazene polymer which includes hydrophilic side groups and interacting side groups which are capable of bonding with a biological agent of interest. The bonding may be by non-covalent bonding.

ION BINDING POLYMERS AND USES THEREOF

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs. 1. A pharmaceutical composition comprising a potassium binding polymer and a pharmaceutically acceptable excipient , the potassium binding polymer being a crosslinked cation exchange polymer comprising a Ca cationic counterion and acid groups in their acid or salt form , the acid groups having an electron-withdrawing substituent attached to a carbon atom alpha or beta to the acid group.2. The pharmaceutical composition of wherein the electron-withdrawing substituent is selected from the group consisting of a hydroxyl group claim 1 , an ether group claim 1 , an ester group claim 1 , and a halide atom.3. The pharmaceutical composition of wherein the acid group is carboxylic.4. The pharmaceutical composition of wherein the acid group is phosphonic.5. The pharmaceutical composition of wherein the potassium-binding polymer comprises a crosslinked carboxylic polymer having fluoride attached to the carbon atom alpha to the carboxylic acid group.6. The pharmaceutical composition of wherein the potassium binding polymer has a swelling ratio of less than about 5.7. The pharmaceutical composition of wherein the potassium binding polymer has a swelling ratio of less than about 3.8. The pharmaceutical composition of wherein the ionization of the acid groups is greater than about 75% at the physiological pH in the colon.9. The pharmaceutical composition of wherein the potassium-binding polymer is in a bead form.10. The pharmaceutical composition of in the form of a chewable ...

ION BINDING POLYMERS AND USES THEREOF

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs. 1. A method for treating hyperkalemia comprising administering a potassium binding polymer to an animal subject in need thereof , the potassium binding polymer being a crosslinked cation exchange polymer comprising acid groups in their acid or salt form , and the acid groups having an electron-withdrawing substituent attached to a carbon atom alpha or beta to the acid group.2. The method of wherein the electron-withdrawing substituent is selected from the group consisting of a hydroxyl group claim 1 , an ether group claim 1 , an ester group claim 1 , and a halide atom.3. The method of wherein the acid group is carboxylic.4. The method of wherein the acid group is phosphonic.5. The method of wherein the potassium-binding polymer comprises a crosslinked carboxylic polymer having fluoride attached to the carbon atom alpha to the carboxylic acid group.6. The method of wherein the potassium binding polymer has a swelling ratio of less than about 5.7. The method of wherein the potassium binding polymer has a swelling ratio of less than about 3.8. The method of wherein the subject is a human.9. The method of wherein the pharmaceutical composition is administered in the form of a chewable tablet.10. The method of wherein the potassium-binding polymer is administered in a dose of about 0.5 gram/day to about 30 grams/day.11. The method of wherein the ionization of the acid groups is greater than about 75% at the physiological pH in the colon.12. The method of wherein the ...

Ion binding polymers and uses thereof

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

BIOCOMPATIBLE POLYMERS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM

A process for treating fibroses including administering a therapeutically effective amount of a pharmaceutical composition which includes at least one biocompatible polymer of the following general formula (I): AXYwherein: A represents a monomer selected from the group consisting of a sugar or —(O—CH—CH—CO)—, X represents a carboxyl group bonded to monomer A, Y represents a sulfate or sulfonate group bonded to monomer A a represents the number of monomers A such that the mass of the polymers of formula (I) is greater than approximately 5,000 da, x represents a substitution rate of the monomers A by the groups X, which is between approximately 20 and 150%, and y represents a substitution rate of the monomers A by the groups Y, which is between approximately 30 and 150%. 118-. (canceled)20. A process for treating and/or preventing aging comprising administering , to a patient in need thereof , a therapeutically effective amount of the pharmaceutical composition which comprises at least one biocompatible polymer of the following general formula (I):{'sub': a', 'x', 'y, 'AXY'}wherein:A represents a monomer,X represents a carboxyl group bonded to monomer A and is contained within a group according to the following formula: —R—COO—R′, in which R is a bond or an aliphatic hydrocarbon chain, optionally branched and/or unsaturated, and which can contain one or more aromatic rings except for benzylamine and benzylamine sulfonate, and R′ represents a hydrogen atom or a cation,{'sub': 3', '3', '3, 'Y represents a sulfate or sulfonate group bonded to monomer A and is contained within a group according to one of the following formulas: —R—O—SO—R′, —R—N—SO—R′, —R—SO—R′, in which R is a bond or an aliphatic hydrocarbon chain, optionally branched and/or unsaturated, and which can contain one or more aromatic rings except for benzylamine and benzylamine sulfonate, and R′ represents a hydrogen atom or a cation,'}a represents the number of monomers A such that the mass of the at least ...

Novel Composition

An oral care compositon is described for use in the treatment or alleviation of the symptoms of dry mouth comprising polyvinyl pyrrolidone (PVP) or a derivative thereof, an anionic mucoadhesive polymer and an orally acceptable carrier or excipient. 1. A method of treating xerostomia by administering to a person in need thereof a composition comprising polyvinyl pyrrolidone (PVP) or a derivative thereof , an anionic mucoadhesive polymer selected from carboxymethyl cellulose and xanthan gum and mixtures thereof and an orally acceptable carrier or excipient.2. A method according to wherein the composition is in the form of a mouthwash or mouthspray.3. A method according to wherein the composition comprises PVP or VP/VA copolymer.4. A method according to wherein the PVP or derivative thereof is present in the amount of 0.1 to 20% w/w.5. A method according to wherein the anionic mucoadhesive polymer is present in the range 0.02 to 20% w/w.6. A method according to wherein the ratio of PVP or a derivative thereof to the anionic mucoadhesive polymer is from 5:1 to 1:1. This application is a divisional of U.S. application No. 11/572,751 filed Aug. 15, 2008 which is a 371 of PCT/EP2005/008327 filed Jul. 29, 2005 which claims the priority of GB 0502077.1 filed Feb. 1, 2005 and GB 0417193.0 filed Aug. 2, 2004.The present invention relates to mucoadhesive agent-containing compositions for oral use, such as toothpastes, sprays, mouthwashes, gels, lozenges, chewing gums, tablets, pastilles, instant powders, oral strips and buccal patches etc, and to the use of such compositions as an oral lubricant and to alleviate the discomfort associated with xerostomia.Xerostomia, or dry mouth, is a condition in which an excessive dryness within the oral cavity occurs. Xerostomia is not itself a disease, but a symptom of various medical conditions, a side effect of radiation to the head and neck, or a side effect of a variety of medications. Xerostomia is a common complaint found often among ...

Use of PVP-Iodine Liposomes for Treatment of Herpes

The invention concerns a method for the production of a pharmaceutical preparation for the treatment of Herpes forms that is characterized in, that the preparation comprises at least one antiseptic compound associated with a particular carrier. 1. A method of treating skin lesions , skin blisters , or skin itchiness caused by herpes infections in a subject , the method comprising topically administering to a subject in need of said treating a preparation comprising PVP-iodine combined with a liposome , the PVP-iodine combined with a liposome provided in an amount effective to reduce herpes viral load , and at the same time reduce pain and itchiness of said skin lesions , skin blisters and skin , and wherein the method suppresses the formation of scar tissue , neoplasms , and intergrowth through the action of PVP-iodine combined with a liposome as a single active ingredient.2. The method of claim 1 , wherein the preparation further comprises a wound-healing promoting agent.3. The method of claim 2 , wherein the wound-healing promoting agent is selected from the group consisting of dexpanthenols claim 2 , allantoines claim 2 , azulenes claim 2 , tannins and vitamins.4. The method of claim 3 , wherein the wound-healing promoting agent is a vitamin selected from the group consisting of vitamin B and derivatives thereof.5. The method of claim 1 , wherein the liposome has a size in a range between approximately 1 μm and approximately 100 μm.6. The method of claim 1 , wherein the liposome has a size in a range between approximately 1 μm and approximately 50 μm.7. The method of claim 1 , wherein the liposome has a size in a range claim 1 , or between approximately 1 μm and approximately 25 μm.8. The method of claim 1 , wherein the liposome releases the PVP-iodine over an extended time period.9. The method of claim 8 , wherein the liposome releases the PVP-iodine over a time period of several hours duration.10. The method of claim 1 , wherein the preparation further ...

Enteral administration of sorbent polymer for treatment and prophylaxis of inflammation

The invention provides a method of ameliorating inflammation in a patient involving administering to the patient a therapeutically effective dose of composition including polystyrene divinyl benzene copolymer and a polyvinyl pyrrolidone polymer. More particularly, the method relates to using these polymers as an enteral sorbent preparation to remove inflammatory mediators, such as cytokines, from the intestinal lumen. The polymers can be in the form of a preparation of polystyrene divinyl benzene copolymer beads with a biocompatible polyvinyl pyrrolidone polymer coating.

Compositions and Methods for Promoting the Healing of Tissue of Multicellular Organisms

Compositions are provided for promoting healing of tissue of a vertebrate organism. The compositions can be for internal administration of a therapeutically effective amount of pharmacologically active, protease inhibiting, aqueous media soluble polysulfonated materials in salt form and associated with a secondary material to reduce one or more of inflammation, bacterial proliferation, proteolytic activity, and cancerous cell growth. The compositions may additionally or alternatively be cross-linked so as to alter the solubility of these pharmacologically active salts or slow dissolution by providing biodegradable cross-linkers. Compositions for healing the tissue of a multicellular organism are provided that can include a polysulfonated material in a liquid mixture, as solid particles or constructs that may or may not biodegrade or deliver a pharmacologically relevant value. Some of the compositions are also provided for inclusion into a device for preventing infection, reducing inflammation, and preserving the activity of a protein or protein drug.

TOPICAL ANTISEPTIC SYSTEM

Novel antimicrobial compositions and kits thereof containing these antimicrobial compositions, methods of manufacture and methods of use thereof are disclosed. The novel aqueous transdermal or topical delivery systems are useful, inter alia, for treatment of various microbial infections, including for use on tissue infections, particularly skin antisepsis and/or nasal mucosal tissue antisepsis to a mammalian host in need thereof. 137-. (canceled)38. A method of disinfecting tissue comprising: an iodophor comprising a carrier selected from the group consisting of a polyvinylpyrrolidone, a copolymer of N-vinyl lactam, a polyether glycol, a polyvinyl alcohol, a polyacrylamide, a polysaccharide, and combinations thereof; wherein the iodophor is present in an amount sufficient to provide an available iodine concentration of at least 0.25 wt-%;', 'a second antimicrobial agent;', 'a nonionic or anionic surfactant;', 'a thickening agent comprising a nonionic cellulose derivative or nonionic copolymer, or combination thereof; and', 'water;', said antiseptic composition is substantially free of any hydroxycarboxylic acid buffer; and', 'said antiseptic composition is substantially free of any fragrance; and, 'wherein], 'applying directly to tissue an antiseptic composition at use concentration, wherein the use concentration of the antiseptic. composition comprisesallowing the antiseptic composition to remain on the tissue; wherein the composition has a pH of 1.5 to 6.5.3941-. (canceled)42. A method according to wherein the nonionic copolymer comprises hydrophilic and hydrophobic regions.43. A method according to claim 42 , wherein the nonionic copolymer comprises a poloxamer.44. (canceled)45. A method of disinfecting skin of a subject comprising: prior to an invasive procedure claim 42 , [{'sub': '2', 'a first antimicrobial agent selected from the group consisting of I, an iodophor, and a combination thereof, wherein the antimicrobial agent is present in an amount sufficient ...

OPHTHALMIC COMPOSITION COMPRISING PVP-I

An ophthalmic composition includes Povidone-iodine (PVP-I) at a concentration of between 0.2%-1.0% (w/w). The ophthalmic composition has an aqueous phase and an oil phase, the oil phase constituting medium-chain triglycerides and the oil phase constituting less than 3% of the total weight of the composition. 113.-. (canceled)14. An ophthalmic composition comprising an aqueous phase , an oil phase , and Povidone-iodine (PVP-I) at a concentration of between 0.2%-1.0% (w/w) , said oil phase consisting of medium-chain triglycerides and said oil phase comprising less than 3% of a total weight of said composition.15. The ophthalmic composition according to claim 14 , wherein said PVP-I is at a concentration of between 0.4 and 0.8% w/w.16. The ophthalmic composition according to claim 14 , wherein said triglycerides are selected from one or more of caproic acid claim 14 , caprylic acid claim 14 , capric acid and lauric acid.17. The ophthalmic composition according to claim 14 , wherein said triglycerides are present in amounts of between 0.05 and 1% w/w.18. The ophthalmic composition according to claim 14 , further comprising a surfactant claim 14 , wherein said surfactant is in amounts of between 0.05 and 4% w/w and said surfactant is d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS).19. The ophthalmic composition according to claim 18 , further comprising an iodide in amounts of between 0.01 and 1.0% w/w claim 18 , wherein said iodide is potassium iodide or sodium iodide.20. The ophthalmic composition according to claim 14 , which is buffered claim 14 , with phosphate or citrate buffer claim 14 , in a pH range of between 4.5 and 6.5.21. The ophthalmic composition according to claim 14 , further comprising osmotizing agents selected from glycerol and sodium chloride and/or viscosizers.22. The ophthalmic composition according to claim 14 , comprising:PVP-I 0.4-0.8% w/w;medium chain triglycerides 0.1-0.9% w/w;TPGS 0.2-2.0% w/w;water;having a pH of between 4.5 and 6.5 ...

Novel ophthalmic composition and methods of use

Described are stable topical formulations useful in the treatment of viral infection, demodex infection and bacterial infection of the eye, and methods of using the compositions for treating viral infection, demodex infection and bacterial infection of the eye.

SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION

Provided herein are pre-formulations forming a biocompatible hydrogel polymer comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the biocompatible hydrogel polymer covers a wound in a mammal and adheres to the surrounding skin tissue. In other embodiments, the hydrogel polymer is delivered into a joint space to treat joint disease or navicular disease. 115-. (canceled)16. A would healing solid polyglycol-based , fully synthetic , pre-formulation , comprising: (a) at least one solid first compound comprising more than two nucleophilic groups; (b) at least one solid second compound comprising more than two electrophilic groups; (c) optionally , a solid buffer component; (d) optionally , a therapeutic agent; and (e) optionally , a solid viscosity enhancer ,wherein the solid polyglycol-based, fully synthetic, pre-formulation polymerizes and/or gels at a target site of the wound to form a polyglycol-based, fully synthetic, biocompatible hydrogel polymer after addition of a liquid component,wherein the liquid component does not contain any first compound or second compound, and provided that the solid polyglycol-based, fully synthetic, pre-formulation does not contain any aqueous component.17. The wound healing solid polyglycol-based , fully synthetic , pre-formulation , wherein the therapeutic is a solid therapeutic agent.18. The wound healing solid polyglycol-based , fully synthetic , pre-formulation , wherein the liquid component comprises water , saline , a buffer , a therapeutic agent , or a combination thereof.19. The wound healing solid polyglycol-based , fully synthetic , pre-formulation , wherein the solid first compound is a MULTIARM (5k-50k) polyol derivative comprising polyglycol subunits and more than two nucleophilic groups , and wherein the solid second compound is a MULTIARM (5k-50k) polyol derivative ...

Oral sorbent for removing toxins of kidney failure combining anion and cation exchangers

Oral sorbent compositions that bind small and charged toxins and methods of use. 1. A novel oral sorbent therapy for removing uremic toxins from the gut comprised of:an ion exchange mixture including a hydrogen-loaded cation exchanger and an hydroxide-loaded anion exchanger.2. The therapy of wherein the cation exchanger is non-specific.3. The therapy of wherein the cation exchanger binds both monovalent and divalent cations.4. The therapy of wherein the cation exchanger is polystyrene sulfonate or zirconium phosphate.5. The therapy of wherein the cation exchanger is zirconium phosphate.6. The therapy of wherein the cation exchanger is selective for exchange of monovalent cations.7. The therapy of wherein the monovalent cations are selected from the group consisting of potassium claim 6 , sodium and ammonium.8. The therapy of wherein the cation exchanger is zirconium cyclosilicate.9. The therapy of wherein the anion exchanger is an inorganic compound.10. The therapy of wherein the anion exchanger is zirconium oxide.11. The therapy of wherein the amount and capacity of the cation exchanger can be increased versus the amount and capacity of the anion exchanger.12. The therapy of wherein the increase provides binding of monovalent cations and anions similar to that of the selective cation exchanger.13. The therapy of wherein amount of anion exchanger can be diminished to provide approximately equal ion exchange to the cation exchanger.14. The therapy of wherein the mixture may also include magnesium or calcium salts.15. The therapy of wherein the mixture may also include magnesium carbonate or calcium acetate.16. The therapy of wherein the cation exchanger is partially loaded with calcium or magnesium to prevent or diminish removal of calcium or magnesium divalent cations.17. The therapy of wherein the cation and anion exchangers are given in proportions to provide approximately equal binding capacity for anions and cations. This application is a U.S. non-provisional ...

THIOLATED PEG-PVA HYDROGELS

A method of forming thiolated poly(vinyl alcohol) hydrogels including reacting, in the presence of an acid, compounds containing a thiol functional group and a hydroxyl reactive group with one or more hydroxyl groups of poly(vinyl alcohol) via said hydroxyl reactive group, thereby forming thiolated poly(vinyl alcohol). The method further including reacting the thiol functional group of said compounds with a thiol reactive group of a crosslinker, thereby forming a hydrogel. 1. A method of forming thiolated poly(vinyl alcohol) hydrogels , comprising:reacting, in the presence of an acid, compounds each including a thiol functional group and a hydroxyl reactive group with one or more hydroxyl groups of poly(vinyl alcohol) via said hydroxyl reactive group, thereby forming thiolated poly(vinyl alcohol); andreacting said thiol functional group of said compounds with a thiol reactive group of a crosslinker, thereby forming a hydrogel.3. The method of claim 1 , wherein said thiol containing compound comprises 3-mercaptopropionic acid.4. The method of claim 1 , wherein said acid is selected from the group consisting of: hydrochloric acid claim 1 , sulfuric acid and phosphoric acid.5. The method of claim 1 , wherein reacting said hydroxyl reactive groups of said compounds with said hydroxyl groups of said poly(vinyl alcohol) is performed at a temperature in the range of 40° C. to 95° C.7. The method of claim 1 , wherein said compounds include amino acids.8. The method of claim 1 , wherein said crosslinker is poly(ethylene glycol).9. The method of claim 8 , wherein said poly(ethylene glycol) is selected from one or more of the following forms of poly(ethylene glycol): linear claim 8 , multi-armed and dendrimer.12. The method of claim 1 , wherein said crosslinker is selected from the group consisting of tocotrienol and lycopene.13. The method of claim 1 , wherein reacting said thiolated poly(vinyl alcohol) with a crosslinker is performed at a temperature in the range of 20° C. ...

COMPOSITION FOR PURIFICATION OF BIOFLUIDS

Disclosed is a composition for the purification of biofluids, for example, for hemodialysis and peritoneal dialysis, comprising an osmotic agent and a toxin-removal reagent, wherein the toxin-removal reagent can remove a toxin from a biofluid under a condition for osmosis. Provided are a dialysis solution and a kit comprising the aforementioned composition, a method for removing a toxin from a biofluid using the aforementioned composition, and a method for treating a toxin-related disease. 1. A composition comprising an osmotic agent and a toxin-removal reagent , wherein the osmotic agent provides an osmotic pressure substantially equal to or higher than that of a biofluid , and the toxin-removal reagent reduces a toxin in the biofluid under a condition for osmosis.2. The composition according to claim 1 , wherein the toxin-removal reagent reduces free amount claim 1 , non-free amount claim 1 , and/or total amount of the toxin in the biofluid.3. (canceled)4. (canceled)5. The composition according to claim 1 , wherein the toxin-removal reagent has one or more characteristics selected from the group consisting of: 1) having a porous structure; 2) capable of forming a charged structure; 3) capable of binding to the toxin through a non-covalent bond or a covalent bond or an ionic bond; and 4) capable of degrading the toxin.6. The composition according to claim 5 , wherein the toxin-removal reagent has a porous structure claim 5 , and the porous structure has one or more of the following characteristics:{'sup': 2', '2, '1) having a specific surface area of 70 cm/g−1000 m/g;'}2) having a pore size in a range of 0.1 nm-10 μm;3) having a pore size distribution of 0.1 nm-100 μm;4) having a porosity of about 5-95%; and5) capable of adsorbing the toxin at an adsorption rate of at least 0.2 mg/g.7. The composition according to claim 6 , wherein the toxin-removal reagent having a porous structure is selected from the group consisting of a silicon-based porous material claim 6 , ...

MINERAL SALT-SULFONIC ACID COMPOSITIONS AND METHODS OF USE

The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions. 1. Method of treating mucosal disorders with a composition comprising zinc gluconate , taurine and polyvinylpyrrolidone (PVP) , said method comprising:applying to each dermal area in need thereof a pharmaceutically effective amount of said composition.2. The method according to claim 1 , wherein said composition comprises between 0.25% w/w to 5.5% w/w zinc gluconate claim 1 , between 0.25% w/w to 30% w/w taurine and from 0.04% w/w to 15% w/w PVP.3. The method according to claim 2 , wherein said composition comprises from between 0.20% w/w to 5.5% w/w zinc gluconate.4. The method according to claim 2 , wherein said composition comprises from between 0.5% w/w to 8.0% w/w taurine.5. The method according to claim 2 , wherein said composition comprises from between 0.5% w/w/ to 4.0% w/w taurine.6. The method according to claim 1 , wherein said composition comprises 0.5% w/w zinc gluconate claim 1 , 1.0% w/w taurine and 4.0% w/w PVP.7. The method according to claim 1 , wherein said composition comprises comprises 0.5% w/w zinc gluconate claim 1 , 1.0% w/w taurine and 8.0% w/w PVP.8. The method according to claim 1 , wherein said composition comprises comprises 2.0% w/w zinc gluconate claim 1 , 4.0% w/w taurine and 4.0% w/w PVP.9. The method according to claim 1 , wherein said composition is in the form of a liquid claim 1 , a solid claim 1 , a gel claim 1 , a paste claim 1 , an emulsion claim 1 , an ointment claim 1 , a foam or a spray.10. The method according to claim 1 , wherein said composition is delivered by a vehicle selected from the group consisting of a sponge claim 1 , gel cap claim 1 , suppository and a lozenge.11. The method according to claim 1 , wherein said composition has a pH between 3.5 ...

NOVEL OPHTHALMIC COMPOSITION AND METHODS OF USE

Described are stable topical formulations useful in the treatment of viral infection, demodex infection and bacterial infection of the eye, and methods of using the compositions for treating viral infection, demodex infection and bacterial infection of the eye. 2. The composition of claim 1 , comprising 0.15% to 1.0% PVP-I.3. The composition of claim 1 , comprising 0.25% to 0.5% PVP-I.4. The composition of claim 1 , comprising about 0.25% PVP-I.5. The composition of claim 1 , comprising 30% to 70% DMSO.6. The composition of claim 1 , comprising 40% to 49% DMSO.7. The composition of claim 1 , comprising 44% DMSO.8. The composition of claim 1 , comprising 2% to 3% gelling agent.29. The composition of comprising 3% gelling agent.11. The composition of claim 10 , wherein the co-solvent is water or aqueous isotonic solution.12. A stable gel composition of claim 1 , wherein claim 1 , the composition is a topical ophthalmic preparation wherein each ingredient is ophthalmically acceptable claim 1 , andsaid ophthalmic gel composition retains at least 85% of titratable iodine in povidone-iodine starting material for at least 72 hours.13. The stable gel composition of wherein the composition retains at least 85% of titratable iodine in povidone-iodine starting material for at least one month.14. The stable gel composition of wherein the composition retains at least 85% of titratable iodine in povidone-iodine starting material for up to 12 months.15. A method of treating an infectious condition of the eye or eyelid claim 12 , said method comprising the step of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'applying an effective amount of a stable, topical ophthalmic gel composition of to a site of the infection as needed to reduce or eliminate the infection.'}16. The method of wherein said infectious condition is selected from the group consisting of blepharitis claim 15 , conjunctivitis claim 15 , corneal ulcer claim 15 , bacterial keratitis claim 15 , viral keratitis ...

COMPOSITIONS AND METHODS FOR CELL KILLING

A solid buffer including one or more ion exchange materials, wherein said solid buffer has a volumetric buffering capacity greater than about 20 mM H/(L·pH unit) and further wherein, when said material is in an environment capable of transporting H ions, said solid buffer is adapted to cause the death of at least one target cell within or in contact with said environment. A selectively permeable barrier layer may be provided covering the solid buffer. 143-. (canceled)44. A method of generating a change in a cellular process of a target eukaryotic cell , said method comprising contacting the target cell with a solid buffer so as to alter an intracellular pH value in at least a portion of said target cell , thereby generating said change in a cellular process of a target cell , wherein said solid buffer comprises one or more solid ion exchange materials having one or more functional groups selected to dissociate H+ ions , wherein said solid buffer having volumetric buffering capacity greater than about 20 mM H+/(L·pH unit) in an environment capable of transporting H+ ions , said solid buffer comprises a sulfonated polystyrene polymer or a sulfonated tetrafluoroethylene copolymer and is adapted to cause the death of at least one target cell within or in contact with said environment.4568-. (canceled)69. An article of manufacture comprising:(i) a support; and(ii) a solid buffer layer being attached to at least part of a surface of said support, said solid buffer comprises a buffering layer and an ion permeable layer being disposed on an external surface of said buffering layer,wherein said solid buffer comprises one or more solid ion exchange materials having one or more functional groups selected to dissociate H+ ions, wherein said solid buffer having volumetric buffering capacity greater than about 20 mM H+/(L·pH unit) in an environment capable of transporting H+ ions, said solid buffer comprises a sulfonated polystyrene polymer or a sulfonated tetrafluoroethylene ...

METHOD OF PROPHYLAXIS OF ZIKA VIRUS INFECTION

Provided herein are methods for preventing transmission of Zika virus, and of preventing diseases, disorders and symptoms associated with Zika virus infections, in particular for preventing transmission during sexual intercourse. The methods comprise topical administration of a macromolecule comprising a dendrimer of 1 to 8 generations with one or more sulfonic acid- or sulfonate-containing moieties attached to one or more surface groups of the dendrimer. Also provided herein are related uses, compositions, devices and systems. 1. A method of preventing or reducing the likelihood of transmission of Zika virus during sexual intercourse to a first individual from a second individual infected with Zika virus , comprising:topically administering to the first and/or second individual an effective amount of a macromolecule or a pharmaceutically acceptable salt thereof, wherein the macromolecule comprises a dendrimer of 1 to 8 generations with one or more sulfonic acid- or sulfonate-containing moieties attached to one or more surface groups of the dendrimer.2. A method of preventing or reducing the likelihood of a disease , disorder or symptom associated with a Zika virus infection in a first individual , by preventing transmission of Zika virus during sexual intercourse to the first individual from a second individual infected with Zika virus , the method comprising:topically administering to the first and/or second individual an effective amount of a macromolecule or a pharmaceutically acceptable salt thereof, wherein the macromolecule comprises a dendrimer of 1 to 8 generations with one or more sulfonic acid- or sulfonate-containing moieties attached to one or more surface groups of the dendrimer.3. A method as claimed in claim 1 , wherein the macromolecule or pharmaceutically acceptable salt thereof is a dendrimer comprising lysine building units of from 3 to 6 generations claim 1 , and the sulfonic acid- or sulfonate-containing moieties are napthyldisulfonate moieties ...

Composition and method for arresting blood flow and for forming a persistent microbial barrier

A composition and method useful in promoting healing of a bleeding wound site. The composition preferably includes a substantially anhydrous acid form of a cation exchange resin, which when applied over blood, provides an antimicrobial against planktonic microorganisms and biofilms in the wound. The resin is also capable, when applied in sufficient quantities, of providing a continuing and persistent antimicrobial against planktonic microorganisms and biofilms through dehydration and ion exchange with cations present in the blood and other body fluids. When the resin has a concentration of at least 26 mg/ml, it provides a >3 log reduction in biological activity of MRSA, MRSE and Pseudomonas aeruginosa.

Polymer/Copper Combination for Targeted Cancer Therapy

Polymer/copper combinations that can selectively target and kill cancer cells are described. Materials can include the reaction product of a biocompatible hydrophilic polymer and pyridine-2-thiol containing monomer. The copolymer reaction product can include pyridine-2-thiol side groups pendant to the backbone via a disulfide linkage. The hydrophilic component can form the polymer backbone and/or can form hydrophilic pendant groups off of the backbone. Copper ions can be associated with the copolymer. 1. A polymer/copper combination comprising a biocompatible copolymer , the biocompatible copolymer comprising;a first component, the first component containing an acrylamide or an acrylate, the first component comprising a hydrophilic portion;a second component, the second component containing an acrylamide or an acrylate, the second component comprising pyridine-2-thiol groups, the pyridine-2-thiol groups being pendant to a backbone of the biocompatible copolymer via a disulfide linkage; andcopper ions complexed with the biocompatible copolymer via chelation of the copper ions with the pyridines of the pyridine-2-thiol groups.2. The polymer/copper combination of claim 1 , wherein the polymer/copper combination is in the form of a particle; the hydrophilic portion being primarily on an exterior surface of the particle.3. The polymer/copper combination of claim 1 , the hydrophilic portion comprising hydrophilic groups pendant to the polymer backbone.4. The polymer/copper combination of claim 3 , wherein the pendant hydrophilic groups comprise poly(ethylene glycol).5. The polymer/copper combination of claim 4 , wherein the pendant hydrophilic groups comprise poly(ethylene glycol) methacrylate.6. The polymer/copper combination of claim 1 , wherein the first component comprises poly(ethylene glycol) claim 1 , poly(N-isopropylacrylamide) (polyNIPAAm) claim 1 , poly(N-(2-hydroxypropyl)methacrylamide) (polyHPMA) claim 1 , poly(acrylic acid) (PAAc) claim 1 , poly(DL-lactic ...

INDUCING CASPASE ACTIVITY

Embodiments are directed towards methods of inducing caspase activity. The methods include contacting a cell with a treatment compound represented by the following Formula (I): where Ris selected from hydrogen or an alkyl group having from 1 to about 16 carbon atoms; Ris selected from a hydroxyl group, a tosylate group, an alkoxy group of the formula ORwhere Ris selected from an alkyl group having from 1 to about 16 carbon atoms, or an ester group of the formula OCOR, where Ris an alkyl group having from 1 to about 16 carbon atoms, and n is from 4 to 46,000, with the proviso that when Ris hydrogen and Ris a hydroxy group the treatment compound has a number average molecular weight from 10,100 to 2,000,0000 g/mol. 2. The method of claim 1 , wherein the treatment compound has a number average molecular weight from 200 to 2 claim 1 ,000 claim 1 ,000 g/mol.3. The method of claim 1 , wherein the treatment compound has a 0.001 millimolar to 75 millimolar concentration in a treatment medium.4. The method of claim 1 , wherein the cell is a cancerous cell.5. The method of claim 1 , wherein the caspase is an effector caspase.6. The method of claim 1 , wherein the caspase is selected from caspase 3 claim 1 , caspase 6 claim 1 , caspase 7 claim 1 , or combinations thereof.7. The method of claim 1 , further comprising inciting apoptosis. Embodiments of the present disclosure are directed towards methods inducing caspase activity.Cancer is a group of diseases involving abnormal cell growth. Colorectal cancer, which may be referred to as colon cancer or bowel cancer, is a cancer from uncontrolled cell growth in the colon or rectum.Colorectal cancer is a commonly diagnosed malignancy. Treatments for colorectal cancer can include surgery, radiation therapy, and/or chemotherapy. However, there remains a need for new methods and/or new compositions that may be utilized for treatment.The present disclosure provides methods of inducing caspase activity, the method comprising contacting ...

ANTIMICROBIAL COMPOUNDS AND NANOSTRUCTURES

The present disclosure provides compounds and nanostructures having one or more quaternary ammonium salts, compositions including the compounds and nanostructures, and methods useful for treating conditions using the compounds, nanostructures, and compositions. In at least one aspect, a compound is represented by formula (I): 3. The nanorod of claim 1 , wherein the second compound comprises a pyridyl disulfide moiety.5. The nanorod of claim 1 , wherein Q is chloro.8. The nanorod of claim 1 , wherein the first compound is a pharmaceutically acceptable salt of a halide.9. The nanorod of claim 8 , wherein the salt is an iodo salt.10. The nanorod of claim 1 , wherein a ratio of the integer n to the integer m is from 5:1 to 15:1.11. The nanorod of claim 1 , wherein the nanorod has a diameter from about 10 nm to about 20 nm.12. The nanorod of claim 1 , wherein the nanorod has a length from about 1 micron to about 2 microns.14. A gel comprising the nanorod of .15. The gel of claim 14 , wherein the gel is an aqueous gel and the gel comprises from 2 wt % to 16 wt % nanorod claim 14 , based on the total weight of the gel.18. The nanoworm of claim 16 , wherein the second compound comprises a pyridyl disulfide moiety.20. The nanoworm of claim 16 , wherein Q is chloro.23. The nanoworm of claim 16 , wherein the first compound is a pharmaceutically acceptable salt of a halide.24. The nanoworm of claim 23 , wherein the salt is an iodo salt.25. The nanoworm of claim 16 , wherein a ratio of the integer n to the integer m is from 5:1 to 15:1.26. A gel comprising the nanoworm of .27. The gel of claim 26 , wherein the gel is an aqueous gel and the gel comprises from 1 wt % to 8 wt % nanoworm claim 26 , based on the total weight of the gel. This application is continuation application of U.S. non-provisional patent application Ser. No. 15/838,751, filed Dec. 12, 2017, which claims priority to and the benefit of U.S. provisional patent application Ser. No. 62/521,040 filed Jun. 16, 2017. ...

METHODS OF USING OPHTHALMIC COMPOSITIONS COMPRISING POVIDONE-IODINE

A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient. 1. An ophthalmic composition suitable for topical administration to an eye , effective for treatment and/or prophylaxis of a microorganism infection or a disorder of at least one tissue of the eye , comprisinga) povidone-iodine in a concentration between 0.01% and 10%, andb) An anti-inflammatory, a steroid, or a combination thereof.2. The ophthalmic composition of wherein said povidone-iodine is between 0.1% and 2.5% by weight.3. The ophthalmic composition of wherein said povidone-iodine is between 0.5% and 2% by weight.4. The ophthalmic composition of wherein a total weight of said povidone-iodine claim 1 , said anti-inflammatory claim 1 , and said steroid is between 0.1% and 4.5% in said solution.5. The ophthalmic composition of wherein said anti-inflammatory agent is selected from the group consisting of ketotifen fumarate claim 1 , diclofenac sodium claim 1 , flurbiprofen sodium claim 1 , ketorlac tromethamine claim 1 , suprofen claim 1 , ceiccoxib claim 1 , naproxen claim 1 , rofecoxib claim 1 , and a combination thereof.6. The ophthalmic composition of wherein said steroid is at a concentration of between 0.01 and 10%.7. The ophthalmic composition of wherein said steroid is at a concentration of between 0.05 and 2%.8. The ophthalmic composition of wherein said steroid is selected from the group consisting of dexamethasone claim 1 , dexamethasone ...

POLYMERS FOR REVERSING HEPARIN-BASED ANTICOAGULATION

Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules. 1 {'sub': '1-18', 'sup': '1', 'claim-text': {'sup': '1', 'wherein each Ris independently selected from a polymer segment having monomer units of Formula (III), 'a core unit, wherein the core unit comprises a Calkyl substituted with three or more of —OR,'}, 'administering a heparin binding polymer to the subject, wherein the heparin binding polymer comprises. A method of counteracting heparin in a subject, the method comprising: wherein n is an integer from 1 to 10,000,', {'sup': 2', '1, 'wherein each Ris independently selected from a hydrogen, carbon, a cationic moiety, R, and a polymer segment of Formula (IV)]}}} [{'sup': '3', 'wherein each Ris independently selected from an oxygen cationic moiety, a hydroxyl, and a polymer segment of Formula (IV),'}, 'wherein m is an integer from 1 to 10,000,', {'sup': '4', 'sub': '1-6', 'wherein each Ris independently selected from a Calkoxy, and'}]}}}wherein the heparin binding polymer comprises 1 to 300 cationic moieties. This application is a continuation under 35 U.S.C. § 120 of U.S. application Ser. No. 15/887,561, filed Feb. 2, 2018, which is a continuation under 35 U.S.C. § 120 of U.S. application Ser. No. 14/629,408, filed on Feb. 23, 2015, now U.S. Pat. No. 10,111,902, which is a continuation under 35 U.S.C. § 120 of U.S. application Ser. No. 14/098,184, filed on Dec. 5, 2013, now U.S. Pat. No. 9,095,666, which is a divisional under 35 U.S.C. § 121 of U.S. application Ser. No. 13/458,899, filed on Apr. 27, 2012, now U.S. Pat. No. 8,637,008, which is a continuation under 35 U.S.C. § 120 of U.S. application Ser. No. 13/504,841, filed on Apr. 27, 2012, now U.S. Pat. No. 8,519,189, which was the U.S. National Phase entry ...

BIOCOMPATIBLE HYDROGEL POLYMER MATRIX FOR DELIVERY OF CELLS

Provided herein are biocompatible hydrogel polymer matrices, which are prepared from biocompatible pre-formulations. The biocompatible pre-formulations comprise at least one nucleophilic compound, at least one electrophilic compound, and at least one cell. The biocompatible hydrogel polymer matrix is bioabsorbable and releases the cell at a target site, achieving a controlled delivery. The biocompatible hydrogel polymer matrix provides a solid support conducive for cell viability and functionality. The cells may grow on the hydrogel polymer surface of inside the hydrogel polymer matrix. 2. The method of claim 1 , wherein the at least one first monomeric unit is PEG-based and fully synthetic claim 1 , and wherein the at least one second monomeric unit is PEG-based and fully synthetic.3. The method of claim 1 , wherein the cell is selected from a mammalian cell claim 1 , insect cell claim 1 , protozoal cell claim 1 , bacterial cell claim 1 , viral cell claim 1 , or fungal cell.4. The method of claim 3 , wherein the mammalian cell is a stem cell.5. The method of claim 3 , The polyglycol-based biocompatible hydrogel polymer matrix of claim 3 , wherein the culture medium comprises a growth factor.6. The method of claim 1 , wherein the first monomeric unit is derived from a MULTIARM-(5-50k)-SH claim 1 , a MULTIARM-(5-50k)-NH2 or a MULTIARM-(5-50k)-AA monomer and the second monomeric unit is derived from a MULTIARM-(5-50k)-SG claim 1 , a MULTIARM-(5-50k)-SGA claim 1 , or a MULTIARM-(5-50k)-SS monomer.7. The method of claim 6 , wherein the first monomeric unit is derived from a 4ARM-5k-SH claim 6 , 4ARM-2k-NH2 claim 6 , 4ARM-5k-NH2 claim 6 , 8ARM-20k-NH2 claim 6 , 4ARM-20k-AA claim 6 , or 8ARM-20k-AA monomer claim 6 , and the second monomeric unit is derived from a 4ARM-10k-SG claim 6 , 8ARM-15k-SG claim 6 , 4ARM-20k-SGA claim 6 , or 4ARM-20k-SS monomer.8. The method of claim 1 , wherein the animal is a human.9. The method of claim 1 , wherein the polyglycol-based ...

ANTIMICROBIAL COMPOUNDS AND NANOSTRUCTURES

The present disclosure provides compounds and nanostructures having one or more quaternary ammonium salts, compositions including the compounds and nanostructures, and methods useful for treating conditions using the compounds, nanostructures, and compositions. In at least one aspect, a compound is represented by formula (I): 2. The method of claim 1 , wherein depositing is performed using an aqueous solution comprising the nanorod.3. The method of claim 1 , further comprising evaporating water of the aqueous solution after depositing the aqueous solution onto the surface.4. The method of claim 1 , wherein depositing the nanorod on the surface is performed by painting the surface claim 1 , dipping the surface claim 1 , spraying the surface claim 1 , taping the surface claim 1 , brush coating the surface claim 1 , spin coating the surface claim 1 , roll coating the surface claim 1 , doctor-blade coating the surface claim 1 , or combination(s) thereof with the nanorod.5. The method of claim 1 , wherein the surface is an interior surface of an aircraft claim 1 , spacecraft claim 1 , or boat.6. The method of claim 1 , wherein the surface is a surface of an air filter of a vehicle.7. The method of claim 1 , wherein the surface is selected from the group consisting of a floor surface claim 1 , a seat surface claim 1 , an overhead bin surface claim 1 , a ceiling surface claim 1 , a door surface claim 1 , a door handle surface claim 1 , and combination(s) thereof.8. The method of claim 1 , wherein Ris pyridyl disulfide.9. The method of claim 1 , wherein Q is chloro.12. The method of claim 1 , wherein the first compound is a pharmaceutically acceptable salt of a halide.13. The method of claim 12 , wherein the salt is an iodo salt.14. The method of claim 1 , wherein a ratio of the integer n to the integer m is about 5:1 to about 15:1.15. The method of claim 1 , wherein the nanorod has a diameter of about 10 nm to about 20 nm.16. The method of claim 1 , wherein the nanorod has ...

Therapy and Cure of Ebola

A therapeutic model for the expedient treatment of deadly pathogens involved in pandemics and bioterrorism related events. The immune pathogenesis of deadly pathogens is redefined in the light of Recent advances in the Fundamentals of Immunology by developing three dimensional understandings of deadly pathogens and its interactions with host and its immune system. The immune pathogenesis of deadly pathogens can be treated expediently and globally with NSPS to mitigate the threat of bioterrorism and pandemics. According to a method for treating deadly pathogens having an immune regulatory molecule, the first step is providing a nano-engineered formulation of sodium polystyrene sulfonate (NSPS) having particle size less than 100 nm. A pharmaceutically effective dose of the NSPS is administered to a patient infected with the pathogen. The immune regulatory molecule is targeted with the NSPS for inhibiting serine protease activation. The therapeutic model is further extended for quarantine purposes to facilitate decontamination measures for patients, hospitals and laboratories. 1. A method for treating deadly pathogens having an immune regulatory molecule comprising:providing a nano-engineered formulation of sodium polystyrene sulfonate (NSPS) having particle size less than 100 nm;administering a pharmaceutically effective dose between 5 and 100 mg of the NSPS suspended in one of sterile water and normal saline to form a mixture to a patient infected with the pathogen; andtargeting the immune regulatory molecule with the NSPS for inhibiting serine protease activation.23-. (canceled)4. The method of claim 1 , wherein immune pathogenesis of deadly pathogens can be treated expediently and globally with NSPS to mitigate the threat of bioterrorism and pandemics.5. The method of claim 4 , wherein said providing step includes one of providing NSPS and providing milligram dosages of NSPS; andwherein said targeting step includes targeting one or more of the group consisting of ...

CLOSTRIDIUM DIFFICILE SPORICIDAL COMPOSITIONS

Disclosed are sporicidal compositions, and methods of use thereof. The sporicidal compositions contain water, an organic solvent, and a spore-germinating agent containing an iodide source, a citrate source or both. The compositions have sporicidal activity against, e.g., spores. The sporicidal compositions can be used alone, or can form part of a disinfecting composition or an antiseptic composition. 1. A sporicidal composition , comprising:water;{'sub': s', 's, 'an amount qof organic solvent, wherein qis about 5% to about 60% w/w; and'}{'sub': g1', 'g1, 'an amount qof spore-germinating agent, wherein qis about 0.05% to about 5% w/w;'} the organic solvent comprises a glycol, glycerine, a glycol ether, a polyethylene glycol or dimethyl isosorbide; and', [{'sub': 'i1', 'an amount qof iodide source, or'}, {'sub': 'c1', 'an amount qof citrate source, or'}, 'a combination thereof;', [{'sub': g1', 'i1', 'c1, 'q≧q+q; and'}, {'sub': i1', 'c1, 'at least one of qand qis at least about 0.05% w/w.'}], 'wherein], 'the spore-germinating agent comprises], 'wherein2. The sporicidal composition of claim 1 , [{'sub': 'i1', 'an amount qof iodide source, or'}, {'sub': 'c1', 'an amount qof citrate source, or'}, 'a combination thereof;', [{'sub': g1', '1i', 'c1, 'q≧q+q; and'}, {'sub': i1', 'c1, 'at least one of qand qis at least about 0.05% w/w.'}], 'wherein], 'the spore-germinating agent consists essentially of, 'wherein3. The sporicidal composition of claim 2 , {'sub': g1', 'i1', 'c1, 'q=q+q.'}, 'wherein4. The sporicidal composition of claim 1 , [{'sub': 'g1', 'qis about 0.10% to about 2.3% w/w; and'}, {'sub': i1', 'c1, 'at least one of qand qis at least about 0.10% w/w.'}], 'wherein529-. (canceled)30. A sporicidal composition claim 1 , comprising:water;{'sub': s', 's, 'an amount qorganic solvent, wherein qis about 5% to about 60% w/w; and'}{'sub': g2', 'g2, 'an amount qspore-germinating agent, wherein qis about 0.03% to about 3.8% w/w;'} the organic solvent comprises a glycol, ...

METHOD AND USE OF COMPOSITIONS COMPRISING LIGNOSULFONATE AND SUBSTANTIALLY FREE OF ELEMENTAL SULPHUR FOR PATHOGENIC ATTENUATION

The use of a composition which comprises lignosulfonate and is substantially free of elemental sulphur for the prevention and treatment of pathogenic and medical disorders in humans and animals. In some embodiments the lignosulfonate is radically polymerized. In some embodiments the composition is formulated as an animal feed additive or supplement. The disclosure also encompasses a method of preventing or treating a pathogenic or medical disorder in a human or animal subject by administering the composition to the subject in an effective dose to attenuate the pathogenic effect of a pathogen or other biological agent, thereby enabling the subject to mount an effective immune response to the pathogen or other biological agent. The composition can be used in the prevention or treatment of a wide range of pathogenic or medical disorders including disorders caused by microbial pathogens; disorders caused by viral pathogens; disorders caused by prions; disorders caused by protists; disorders caused by fungi; disorders caused by parasites; lung and airway disorders; bone, joint and muscle disorders; digestive disorders; hormonal disorders; cancer; auto immune disorders; neurodegenerative disorders; skin disorders; and sexual and reproductive disorders. In one particular embodiment the composition is formulated for treatment of Type I diabetes. 1. The use of a composition comprising lignosulfonate for the prevention and treatment of pathogenic and medical disorders in humans and animals , wherein said composition is substantially free of elemental sulphur.2. The use as defined in claim 1 , wherein said lignosulfonate is radically polymerized lignosulfonate.3. The use as defined in claim 1 , wherein said composition comprises lignosulfonate selected from the group of ammonium lignosulfonate claim 1 , sodium lignosulfonate claim 1 , calcium lignosulfonate and magnesium lignosulfonate.4. The use as defined in claim 1 , wherein said composition is formulated for use as an ...

WOUND HEALING COMPOSITION

The invention discloses a composition comprising hyaluronic acid with a high molecular weight and povidone-iodine in low amount that has advantageous efficacy in enhancing wound healing and maintains high stability. Also disclosed is a method of using the composition of the invention in healing wounds. 1. A wound-healing composition comprising hyaluronic acid with a molecular weight no less than 100 KDa and povidone-iodine at an amount from about 0.005% (w/w) to 0.1% (w/w) based on the total weight of the composition.2. The composition of claim 1 , wherein the hyaluronic acid or its derivative has a molecular weight of about 100 KDa to about 3 claim 1 ,000 KDa.3. The composition of claim 1 , wherein the hyaluronic acid or its derivative has a molecular weight of about 1 claim 1 ,000 KDa to about 3 claim 1 ,000 KDa.4. The composition of claim 1 , wherein the hyaluronic acid or its derivative has a molecular weight of about 1 claim 1 ,000 KDa or about 2 claim 1 ,000 KDa.5. The composition of claim 1 , wherein the amount of the hyaluronic acid or its derivative ranges from about 0.8% (w/w) to about 2.5% (w/w).6. The composition of claim 1 , wherein the amount of the hyaluronic acid or its derivative ranges from about 1.0% (w/w) to about 2.0% (w/w).7. The composition of claim 1 , wherein the amount of the hyaluronic acid or its derivative is about 1.5% (w/w).8. The composition of claim 1 , wherein the amount of povidone-iodine is about 0.01% (w/w) to about 0.25% (w/w).9. The composition of claim 1 , wherein the amount of povidone-iodine is about 0.01% (w/w) to about 0.1% (w/w).10. The composition of claim 1 , wherein the amount of povidone-iodine is about 0.01% (w/w).11. The composition of claim 1 , which is in the form of a gel claim 1 , lotion claim 1 , cream claim 1 , tonic or emulsion.12. The composition of claim 1 , wherein the wound includes surgical wounds; bites; burns; acid and alkali burns; cold burns (frostbite) claim 1 , sun burn claim 1 , minor cuts claim 1 ...

PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMERIC BINDERS WITH NON-HYDROLYSABLE COVALENT BONDS AND THEIR USE IN TREATING CELIAC DISEASE

A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa. 146-. (canceled)47. Food comprising a polymeric binder including a synthetic polymer or copolymer , the synthetic polymer or copolymer comprising one or more of:(a) a copolymer of hydroxyethyl methacrylate (HEMA) and 4-styrene sulfonic acid sodium salt hydrate (SStNa);(b) a copolymer of HEMA and sulfopropyl methacrylate potassium salt (SPMAK);(c) a polymer of 4 styrene sulfonic acid sodium salt hydrate (SStNa); or(d) a polymer of sulfopropyl methacrylate potassium salt (SPMAK).48. The food of claim 47 , wherein the food is a gluten-containing food.49. The food of claim 48 , wherein the food is bread.50. The food of claim 47 , wherein the synthetic copolymer comprises a copolymer of HEMA and SStNa hydrate.51. The food of claim 47 , wherein the synthetic polymer or copolymer comprises a copolymer of HEMA and SPMAK.52. The food of claim 47 , wherein the synthetic polymer or copolymer comprises a polymer of SStNa.53. The food of claim 47 , wherein the synthetic polymer or copolymer comprises a polymer of SPMAK.54. The food of claim 47 , wherein the synthetic polymer or copolymer is linear.55. The food of claim 47 , wherein the synthetic polymer or copolymer is star-shaped.56. The food of claim 55 , ...

NOVEL OPHTHALMIC COMPOSITION AND METHODS OF USE

Described are stable topical formulations useful in the treatment of viral infection, demodex infection, fungal infection and bacterial infection of the eye, and methods of using the compositions for treating viral infection, demodex infection, fungal infection and bacterial infection of the eye. 1. A stable gel composition comprising0.15% to 1.5% povidone-iodine (PVP-I);30% to 97% dimethyl sulfoxide (DMSO);0.25% to less than 2.0% gelling agent; andwater or isotonic co-solventwherein, the composition has a pH less than 4.5, and is free of additional anti-inflammatory drug.2. The stable gel composition of claim 1 , comprising 0.15% to 1.25% PVP-I.3. The stable gel composition of claim 1 , comprising 0.25% to 1.0% PVP-I4. The stable gel composition of claim 1 , comprising about 0.25% PVP-I.5. The stable gel composition of claim 1 , comprising about 0.50% PVP-I.6. The stable gel composition of claim 1 , comprising about 0.75% PVP-I.7. The stable gel composition of claim 1 , comprising 30% to 70% DMSO.8. The stable gel composition of claim 1 , comprising 40% to 49% DMSO.9. The stable gel composition of clam 1 claim 1 , comprising 44% DMSO.10. The stable gel composition of claim 1 , comprising about 0.25% gelling agent.11. The stable gel composition of claim 1 , comprising about 0.50% gelling agent.12. The stable gel composition of claim 1 , comprising about 1.0% gelling agent.13. The stable gel composition of claim 1 , comprising about 1.25% gelling agent.14. The stable gel composition of claim 1 , comprising about 1.50% gelling agent.15. The stable gel composition of comprising 1.75% gelling agent.16. The stable gel composition of wherein the gelling agent is a cellulosic polymer.17. The stable gel composition of wherein the gelling agent is hydroxyethyl cellulose (HEC).18. The stable gel composition of claim 1 , comprising:0.25% PVP-I;44% DMSO;greater than 0.25% and less than 2.0% gelling agent; anda co-solvent, andwherein said composition is steroid-free and NSAID- ...

NOVEL OPHTHALMIC COMPOSITION AND METHODS OF USE

Described are stable topical formulations useful in the treatment of viral infection, demodex infection, fungal infection and bacterial infection of the eye, and methods of using the compositions for treating viral infection, demodex infection, fungal infection and bacterial infection of the eye. 2. The stable gel composition of claim 1 , comprising 0.15% to 1.25% PVP-I.3. The stable gel composition of claim 1 , comprising 0.25% to 1.0% PVP-I4. The stable gel composition of claim 1 , comprising 10% to 70% DMSO.5. The stable gel composition of claim 1 , comprising 30% to 49% DMSO.6. The stable gel composition of claim 1 , comprising about 0.25% gelling agent.7. The stable gel composition of claim 1 , comprising about 0.50% gelling agent.8. The stable gel composition of claim 1 , comprising about 1.0% gelling agent.9. The stable gel composition of claim 1 , comprising about 1.25% gelling agent.10. The stable gel composition of claim 1 , comprising about 1.50% gelling agent.11. The stable gel composition of comprising 1.75% gelling agent.12. The stable gel composition of wherein the gelling agent is a cellulosic polymer.14. The stable gel composition of claim 13 , wherein the co-solvent is water or aqueous isotonic solution.15. (canceled)16. The stable gel composition of claim 1 , wherein claim 1 , the composition is a topical ophthalmic preparation wherein each ingredient is ophthalmically acceptable claim 1 , and said ophthalmic gel composition retains at least 85% of titratable iodine in povidone-iodine starting material for at least 72 hours.17. The stable gel composition of wherein the composition retains at least 85% of titratable iodine in povidone-iodine starting material for at least one month.18. The stable gel composition of wherein the composition retains at least 85% of titratable iodine in povidone-iodine starting material for up to 12 months.19. A method of preventing an infectious condition of the eye or eyelid claim 1 , said method comprising the step ...

COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA

The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance. 2. The calcium salt of claim 1 , wherein the ratio of m to n is from about 70:1 to about 50:1 or from about 70:1 to about 60:1.34.-. (canceled)5. The calcium salt of claim 1 , wherein Y is phenyl.6. The calcium salt of claim 1 , wherein X is absent or phenyl.7. The calcium salt of claim 1 , wherein X is absent and Ris H when XRis attached to the carbon atom substituted with Y.8. The calcium salt of claim 1 , wherein Ris H.9. The calcium salt of claim 1 , wherein Rand Rare each independently H or —S(O)OH.10. Them calcium salt of claim 1 , wherein the potassium binding polymer is characterized by a swelling ratio in water of from about 3 grams of water per gram of polymer to about 8 grams of water per gram of polymer or from about 3 grams of water per gram of polymer to about 4.5 grams of water per gram of polymer.1113.-. (canceled)14. The calcium salt of claim 1 , wherein the potassium binding polymer further comprises substantially spherical particles having a median diameter from about 5 m to about 130 m.15. The calcium salt of claim 14 , wherein the particles have an average particle size Dv(0.9) from about 80 μm to about 130 μm or from about 90 μm to about 120 μm.16. (canceled)17. The calcium salt of claim 14 , wherein the particles have an average particle size Dv(0.9) from about 40 μm to about 70 μm or from about 50 μm to about 60 μm.18. (canceled)19. The calcium salt of claim 14 , wherein the particles have an average particle size Dv(0.5) from about 60 μm to about 90 μm or from about 70 μm to about 80 μm.20. (canceled)21. The calcium salt of claim 14 , wherein the particles have an average particle size Dv(0.5) from about 20 μm to about 50 μm or from about ...

Anionically modified polyallylamine derivative, use of anionically modified polyallylamine derivative as medicine, particularly for propylaxis and treatment of infections of respiratory tract caused by human metapneumovirus (hmpv), human rhinoviruses (hrv), and infection by influenza virus type a (iav) and pharmaceutical composition comprising the anionically modified polyallylamine derivative

The subject of the invention is an N-sulfonic polyallylamine derivative (NSPAH) with Formula 1, wherein R is —SO 3 − or —H, and n is an integer from 150 to 15000; an application of the N-sulfonic polyallylamine derivative as a medicine, particularly for prevention and treatment of respiratory tract infections caused by the human metapneumovirus (hMPV), respiratory tract infections caused by the human rhinoviruses (HRV), and infections caused by the influenza A virus; as well as a pharmaceutical composition comprising the N-sulfonic polyallylamine derivative and application thereof.

BIOADHESIVE COMPOSITION AND DEVICE FOR REPAIRING TISSUE DAMAGE

Provided is a bioadhesive composition and device including same, the composition including a polymeric matrix and at least one synthetic bioadhesive polymer carried by the polymeric matrix, the polymeric matrix including at least one synthetic thermoplastic polymer characterized by one or more of (a) an average molecular weight in the range of between 20,000 Da to 90,000 Da; and (b) it includes polycaprolactone (PCL); wherein exposure to heat causes the bioadhesive composition to transform into a non-solid state and to cohesively adhere to a biological tissue upon subsequent cooling thereof. Also provided herein are methods of preparing the composition or device, and use of the composition or device in therapy, e.g. for treating hernia. 153.-. (canceled)54. A bioadhesive composition , comprising: a polymeric matrix; and at least one synthetic bioadhesive polymer carried by the polymeric matrix , the polymeric matrix comprising at least one synthetic thermoplastic polymer characterized by one or more of the followingan average molecular weight in the range of from 20,000 Da to 90,000 Da, andit comprises polycaprolactone (PCL),wherein exposure to heat causes the bioadhesive composition to transform into a non-solid state and to cohesively adhere to a biological tissue upon subsequent cooling thereof.55. The bioadhesive composition of claim 54 , wherein the at least one thermoplastic polymer consists of a single type of polymer having an average molecular weight in the range of from 40 claim 54 ,000 to 60 claim 54 ,000 or a combination of two or more thermoplastic polymers having an average molecular weight in the range of from 40 claim 54 ,000 to 60 claim 54 ,000.56. The bioadhesive composition of claim 55 , wherein the at least one thermoplastic polymer comprises or consists of PCL.57. The bioadhesive composition of claim 56 , wherein the PCL has an average molecular weight in the range of from 43 claim 56 ,000 to 48 claim 56 ,000.58. The bioadhesive composition of ...

COMPOSITION USING CROSS-LINKED HYALURONIC ACID FOR TOPICAL COSMETIC AND THERAPEUTIC APPLICATIONS

Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin. 1. A topical composition comprising: a polysaccharide gel matrix; and a substance , alone , or in combination with , an effective amount of a therapeutic agent deliverable to a skin surface , wherein the therapeutic agent is a salt , a solvate , a prodrug , or a derivative of the therapeutic agent , and wherein the substance , alone or in combination , is entrapped within the matrix.2. A composition according to claim 1 , wherein the polysaccharide is a cross-linked polymer of hyaluronic acid claim 1 , a salt or a derivative of the polymer.3. A composition according to claim 2 , wherein the polymer is in an equilibrium form and is hylan B.4. A topical composition according to claim 2 , wherein the polymer is in a non-equilibrium form and is hylan B.5. A composition according to claim 1 , wherein the substance is a hydrophilic organic ingredient.6. A composition according to claim 5 , wherein the hydrophilic organic ingredient is an α- claim 5 , β- claim 5 , γ- or δ-hydroxy acid claim 5 , an α-amino acid claim 5 , a β-amino acid claim 5 , a γ-amino acid claim 5 , a δ-amino acid claim 5 , a glycerin claim 5 , a vitamin claim 5 , a vitamin derivative claim 5 , a sugar claim 5 , an essential oil claim 5 , a water-soluble oil claim 5 , a fragrance claim 5 , a natural polymer claim 5 , a synthetic polymer claim 5 , a cross-linked natural polymer claim 5 , a cross linked synthetic polymer claim 5 , a peptide claim 5 , a protein claim 5 , a polysaccharide or a nucleic acid.7. A composition according to wherein the hydrophilic organic ...

Method of treatment or prophylaxis of infections of the eye

A microbial infection in an eye of a subject is treated or prevented by topically administering to the eye an effective amount of a macromolecule or a pharmaceutically acceptable salt thereof that includes a dendrimer of 1 to 8 generations with one or more sulfonic acid- or sulfonate-containing moieties attached to one or more surface groups of the outermost generation of the dendrimer. Compositions containing the macromolecule or salt are useful in these methods.

Controllable self-annealing microgel particles for biomedical applications

A microporous gel system for certain applications, including biomedical applications, includes an aqueous solution containing plurality of microgel particles including a biodegradable crosslinker. In some aspects, the microgel particles act as gel building blocks that anneal to one another to form a covalently-stabilized scaffold of microgel particles having interstitial spaces therein. In certain aspects, annealing of the microgel particles occurs after exposure to an annealing agent that is endogenously present or exogenously added. In some embodiments, annealing of the microgel particles requires the presence of an initiator such as exposure to light. In particular embodiments, the chemical and physical properties of the gel building blocks can be controlled to allow downstream control of the resulting assembled scaffold. In one or more embodiments, cells are able to quickly infiltrate the interstitial spaces of the assembled scaffold.

CATHODE MATERIALS FOR Li-S BATTERIES

Compositions and methods of producing composite materials for use as a cathode in electrochemical cells. Elemental sulfur is mixed with tungsten sulfide (WS) to form a composite mixture. Organic comonomers may be added to the composite mixture. The composite mixture is reacted to form the composite material. Electrochemical cells with cathodes containing the composite material demonstrated improved battery performance. 1. A composite material comprising at least about 50 wt % sulfur derived from elemental sulfur (S) , and about 5-50 wt % tungsten sulfide (WS).2. The composite material of claim 1 , wherein WSis dispersed in the sulfur.3. The composite material of claim 1 , further comprising about 5-10 wt % of one or more comonomers selected from a group consisting of ethylenically unsaturated comonomers claim 1 , styrenic comonomers claim 1 , vinylic comonomers claim 1 , methacrylate comonomers claim 1 , acrylonitrile comonomers claim 1 , allylic monomers claim 1 , acrylate monomers claim 1 , vinylpyridine monomers claim 1 , isobutylene monomers claim 1 , maleimide monomers claim 1 , norbornene monomers claim 1 , monomers having at least one vinyl ether moiety claim 1 , and monomers having at least one isopropenyl moiety.4. The composite material of claim 3 , wherein the sulfur and the one or more comonomers form a sulfur copolymer with WSdispersed therein.5. The composite material of claim 3 , wherein the one or more comonomers are 1 claim 3 ,3-diisopropenylbenzene comonomers.6. An active material for use in a battery electrode claim 1 , said active material comprising the composite material of .7. An electrochemical cell comprising:a. an anode comprising lithium;{'sub': 8', '2, 'b. a cathode comprising a composite material comprising at least about 50 wt % sulfur derived from S, and about 5-50 wt % tungsten sulfide (WS); and'}c. a non-aqueous electrolyte interposed between the cathode and the anode.8. The electrochemical cell of claim 7 , wherein the composite ...

Methods of Promoting Bone Growth and Healing

In one aspect, methods of promoting bone growth are described herein. In some embodiments, a method described herein comprises disposing a graft or scaffold in a bone growth site. The graft or scaffold comprises (a) a polymer network formed from the reaction product of (i) citric acid, a citrate or an ester of citric acid with (ii) a polyol. The graft or scaffold further comprises (b) a particulate inorganic material dispersed in the polymer network.

Arginine-Grafted Bioreducible Polymer Systems and Use in Treatment of Cardiac Conditions

phEPO/ABP polyplexes and methods for the use thereof are disclosed and described. In one embodiment, a phEPO/ABP polyplex may be administered to a subject in a therapeutically effective amount to treat or prevent a cardiac condition. Administration may 5 be made, in some aspects, by intramyocardial injection of a composition or solution containing the phEPO/ABP polyplex.

PHARMACEUTICAL COMPOSITION CONTAINING CELECOXIB

Disclosed herein is a pharmaceutical composition comprising pharmaceutical formulation of complexed Celecoxib and crystalline Celecoxib to provide fast and long lasting continuous pain management with once a daily dosing. The pharmaceutical composition has improved physicochemical properties that provide faster onset of action for acute pain relief and lower GI related side effects for acute pain relief and lower GI related side effects. 117.-. (canceled)19. The method of claim 18 , wherein the pharmaceutical composition comprises 50-200 mg Celecoxib equivalent of the Celecoxib complex.20. The method of claim 18 , wherein the pharmaceutical composition comprises 50-400 mg crystalline Celecoxib.21. The method of claim 18 , wherein the pharmaceutical composition further comprises 40-20 claim 18 ,000 mg pharmaceutically acceptable excipients.22. The method of claim 18 , wherein said crystalline Celecoxib is micronized Celecoxib.23. The method of claim 22 , wherein the main particle size of said micronized Celecoxib is in the range of between 3-10 μm.24. The method of claim 18 , wherein said pharmaceutical composition is suitable for oral administration.25. The method of claim 24 , wherein said pharmaceutical composition is suitable for the preparation of liquid dispersible granule claim 24 , sachet claim 24 , orally disintegrating tablet claim 24 , chewing tablet claim 24 , tablet for solution claim 24 , tablet for suspension and immediate release tablet dosage forms.26. The method of claim 25 , wherein said pharmaceutical composition comprises liquid dispersible granules of the Celecoxib complex and crystalline Celecoxib.27. The method of claim 18 , wherein the Celecoxib complex is prepared by spray drying a solution mixture of 2-propanol and water containing celecoxib claim 18 , the copolymer of vinylpirrolidone and vinyl acetate claim 18 , and the sodium lauryl sulfate.28. A method of treating osteoarthritis claim 18 , rheumatoid arthritis claim 18 , juvenile ...

Novel Nitric Oxide Synthase Agonist Polymers

The invention relates to polymers comprising NOS agonists and one or more monomers selected from the group consisting of lactide, glycolide and epsiloncaprolactone, wherein the NOS agonist is incorporated as repeating monomer units into the body or backbone of the polymer are disclosed. The NOS agonist may comprise one or more carboxylic acid groups and one or more alkylhydroxy groups. In another embodiment, the NOS agonist may comprise a carboxylic acid group and an alkylhydroxy group that can be joined to form a lactone containing cyclic ring. In another embodiment, the NOS agonist comprises HMG CoA reductase inhibitor or statin. 1. A polymer comprising NOS agonist and one or more monomers selected from the group consisting of lactide , glycolide , and epsilon caprolactone , wherein the NOS agonist is incorporated as repeating monomer units into the body of the polymer.2. The polymer of claim 1 , wherein the NOS agonist comprises one or more carboxylic acid groups and one or more alkylhydroxy groups.3. The polymer of claim 1 , wherein the NOS agonist comprises a carboxylic acid group and an alkylhydroxy group that can be joined to form a lactone containing cyclic ring.4. The polymer of claim 1 , wherein the NOS agonist comprises HMG CoA reductase inhibitor or statin.5. The polymer of claim 4 , wherein the statin is selected from the group consisting of velostatin claim 4 , dihydrocompactin claim 4 , carvastatin claim 4 , bevastatin claim 4 , cefvastatin claim 4 , glenvastatin claim 4 , simvastatin claim 4 , lovastatin claim 4 , atorvastatin claim 4 , pravastatin claim 4 , cerivastatin claim 4 , rosuvastatin claim 4 , pitavastatin claim 4 , fluvastatin claim 4 , mevastatin claim 4 , dalvastatin claim 4 , compactin and mixtures thereof.6. The polymer of claim 5 , wherein the statin is selected from the group consisting of simvastatin claim 5 , lovastatin claim 5 , atorvastatin claim 5 , pravastatin claim 5 , cerivastatin claim 5 , rosuvastatin claim 5 , pitavastatin ...

SYNERGISTIC ANTIBACTERIAL ACTIVITY OF MEDIUM POLARITY OILS IN COMBINATION WITH ANTIBACTERIAL AGENTS ON BACTERIAL BIOFILMS

The compositions of the present invention comprise at least one medium polarity oil and at least one antibacterial agent, the combination of which produces a synergistic antibacterial effect against bacterial biofilms. Methods are disclosed for the reduction of bacteria in and/or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms. 1114-. (canceled)115. A method of treating a wound , mucous membrane lesion , or skin lesion infected or contaminated with a bacterial biofilm , the method comprising topically administering to the wound , mucous membrane lesion , or skin lesion a composition comprising a combination of at least one medium polarity oil having an octanol-water partition coefficient (log P) of 0.5 to 2.0 and at least one silver compound , wherein the medium polarity oil is benzyl alcohol or propyl gallate.116. The method of claim 115 , wherein the silver compound is silver nitrate claim 115 , silver sulfadiazine claim 115 , or silver chloride.117. The method of claim 115 , wherein the silver compound is silver nitrate.118. The method of claim 115 , wherein the silver compound is at a concentration of 0.1% w/w to 5% w/w claim 115 , and the medium polarity oil is at a concentration of 1% w/w to 10% w/w.119. The method of claim 115 , wherein the silver compound is at a concentration of 0.1% w/w to 1.5% claim 115 , and the medium polarity oil is at a concentration of 4.5% w/w to 5.5% w/w.120. The method of claim 119 , wherein the silver compound is silver nitrate.121. The method of claim 115 , wherein the composition further comprises a pharmaceutical carrier.122. The method of claim 121 , wherein the pharmaceutical carrier is a lotion claim 121 , solution claim 121 , suspension claim 121 , liquid claim 121 , emulsion claim 121 , cream claim 121 , gel claim 121 , ringing ...

ION BINDING POLYMERS AND USES THEREOF

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs. 1. A pharmaceutical composition comprising a potassium-binding polymer and a pharmaceutically acceptable excipient , wherein said potassium-binding polymer comprises a α-fluoroacrylate polymer crosslinked with divinyl benzene.2. A method of treating a disease comprising administering to an animal subject in need thereof an effective amount of a pharmaceutical composition of .3. A core-shell composition comprising a core and a shell claim 1 , said core comprising a potassium binding polymer selected from polystyrene sulfonate or α-fluoroacrylate polymer crosslinked with divinyl benzene and said shell comprising Eudragit RL 100 claim 1 , Eudragit RS 100 claim 1 , a combination thereof claim 1 , benzylated polyethyleneimine claim 1 , or N-dodecyl polyethyleneimine.4. The composition of wherein said shell comprises a mixture of Eudragit RL 100 and Eudragit RS 100 in a ratio of about 50: about 50.5. The composition of wherein said shell comprises benzylated polyethyleneimine with a degree of benzylation being about 20% to about 99% of nitrogen mole content.6. The composition of wherein said shell comprises N-dodecyl polyethyleneimine with a degree of dodecyl alkylation being about 20% to about 99% of nitrogen mole content.7. The composition of wherein said core-shell composition is synthesized by a Wurster fluid bed coating process or a controlled coating precipitation process.8. The composition of wherein said controlled coating precipitation process is a solvent ...

THERAPEUTIC POLYMER GEL SYSTEM TO PROMOTE HEALING AND PREVENT FIBROSIS AT A WOUND OR SURGICAL SITE

Disclosed herein are therapeutic polymer gel systems for promoting healing of a wound or surgical site in a subject. The therapeutic polymer gel forms a microporous network and may be applied or injected in a fluid form and annealed or crosslinked after application to the wound or surgical site. The microporous gel may optionally contain various therapeutic agents throughout the therapeutic polymer gel which are released. 1. A therapeutic polymer gel system for use in a wound or surgical site comprising:a collection of substantially monodisperse spherical microgel particles having diameters within the range of 35 μm to 1,000 μm comprising a synthetic polymer backbone and annealing components comprising K-peptides and Q-peptides and exhibiting a stiffness within the range of about 10 to 1,000 pascals (Pa) that when exposed to an annealing agent covalently links adjacent spherical microgel particles to form an interconnected porous network from the substantially monodisperse spherical microgels having a mean pore diameter of at least 10 μm.2. The therapeutic polymer gel system of claim 1 , wherein the annealing agent comprises activated Factor XIII.3. The therapeutic polymer gel system of claim 1 , wherein the annealing agent comprises Eosin Y claim 1 , that when exposed to light claim 1 , covalently links adjacent spherical microgel particles.4. The therapeutic polymer gel system of claim 1 , wherein the synthetic polymer backbone comprises poly(ethylene glycol).5. The therapeutic polymer gel system of claim 1 , wherein the collection of substantially monodisperse spherical microgel particles claim 1 , when exposed to the annealing agent claim 1 , further covalently links the spherical microgel particles to adjacent tissue in the wound or surgical site.6. The therapeutic polymer gel system of claim 1 , wherein the collection of substantially monodisperse spherical microgel particles has a coefficient of variation of less than 35% in diameter.7. The therapeutic ...

TOPICAL ANTISEPTIC SYSTEM

Novel antimicrobial compositions and kits thereof containing these antimicrobial compositions, methods of manufacture and methods of use thereof are disclosed. The novel aqueous transdermal or topical delivery systems are useful, inter alia, for treatment of various microbial infections, including for use on tissue infections, particularly skin antisepsis and/or nasal mucosal tissue antisepsis to a mammalian host in need thereof. 137-. (canceled)38. A method of disinfecting tissue comprising: 'an iodophor comprising a carrier selected from the group consisting of a polyvinylpyrrolidone, a copolymer of N-vinyl lactam, a polyether glycol, a polyvinyl alcohol, a polyacrylamide, a polysaccharide, and combinations thereof;', 'applying directly to tissue an antiseptic composition at use concentration, wherein the use concentration of the antiseptic composition comprises a second antimicrobial agent;', 'a nonionic or anionic surfactant;', 'a thickening agent comprising a nonionic cellulose derivative or nonionic copolymer, or combination thereof; and', 'water;', said antiseptic composition is substantially free of any hydroxycarboxylic acid buffer; and', 'said antiseptic composition is substantially free of any fragrance; and, 'wherein], 'wherein the iodophor is present in an amount sufficient to provide an available iodine concentration of at least 0.25 wt-%;'}allowing the antiseptic composition to remain on the tissue; wherein the composition has a pH of 1.5 to 6.5.3941-. (canceled)42. A method according to wherein the nonionic copolymer comprises hydrophilic and hydrophobic regions.43. A method according to claim 42 , wherein the nonionic copolymer comprises a poloxamer.44. (canceled)45. A method of disinfecting skin of a subject comprising: prior to an invasive procedure claim 42 , a first antimicrobial agent selected from the group consisting of 12, an iodophor, and a combination thereof, wherein the antimicrobial agent is present in an amount sufficient to provide an ...

Compositions and methods for treatment of skin infections

A pharmaceutical composition for treating skin infections is described herein. A method using a pharmaceutical composition for treating skin infections is described herein. A pharmaceutical composition for treating skin infections may comprise, in 100 parts of the composition, 1-99 parts of a pharmaceutically acceptable excipient; 99-1 parts of a keratolytic; 99-1 parts ethyl pyruvate; and 99-1 parts povidone iodine. A method for treating skin infections may comprise topical application of a composition to an infected skin cell for a treatment period.

Inhibitors of Kidney Stone Formation and Calcium Deposition

A pharmaceutical composition for the treatment of pathological calculus and plaque formation is provided. The composition includes conjugates of polymers and metal binding agents that are particularly effective in inhibiting crystal nucleation, growth, and aggregation in the body, such as that observed in the formation of kidney stones. The composition is effective at low dosage, thereby avoiding the side effects typically associated with current treatments for kidney stones. The composition is also effective against plaque formation, and may have intrinsic antimicrobial activity. Also provided are methods of treating diseases and surfaces of devices and materials treated with the composition.

BUCKWHEAT HONEY AND POVIDONE-IODINE WOUND-HEALING DRESSING

A wound healing composition and method for treating acute and chronic wounds and skin conditions includes a wound healing composition or formulation including a mixture of buckwheat honey, methylglyoxal and povidone-iodine. 1. A wound-healing composition consisting essentially of:a buckwheat honey and methylglyoxal composition wherein the methylglyoxal is in an amount of from about 500 to about 2000 mg per kg of the buckwheat honey and methylglyoxal composition; anda dilution of povidone-iodine in sterile water;in an amount effective to promote healing of a wound.2. The wound-healing composition of claim 1 , wherein the buckwheat honey is raw.3. The wound-healing composition of claim 1 , wherein the povidone-iodine is in a form of a white powder prior to dilution.4. The wound-healing composition of claim 3 , wherein the povidone-iodine comprises an about 9 to about 12% by volume iodine solution mixed with the sterile water to dilute it to from about 1.5 to about 4.0% by volume.5. The wound-healing composition of wherein the povidone-iodine is in an amount from about .16 to 2.1% wt of the wound healing composition.6. The wound-healing composition of wherein the dilution of povidone-iodine in sterile water consists of about 1 to 5% of povidone-iodine per ml of sterile water.7. The wound-healing composition of which can be provided in a tube or spray.8. The wound-healing composition of further comprising a gelling agent.9. The wound-healing composition of claim 8 , wherein the gelling agent is sufficient to thicken the wound-healing composition and to substantially prevent the wound-healing composition from running and to release a desired amount of the wound-healing composition to the wound.10. A wound-healing dressing comprising:a wound-healing composition consisting essentially of a buckwheat honey and methylglyoxal composition wherein the methylglyoxal is in an amount of from about 500 to about 2000 mg per kg of the buckwheat honey and methylglyoxal composition, a ...

METAL OXIDE AND POLYMER-CONTROLLED DELIVERY SYSTEMS, SUNSCREENS, TREATMENTS, AND TOPICAL COATING APPLICATORS FOR ANTIFUNGAL AND ANTIMICROBIAL AGENTS

A dose applicator for preparing a mixture at a point of use includes a housing defining an interior and an opening. First and second ampoules are contained in the interior, wherein the first ampoule contains a first component and the second ampoule contains a second component comprising one or more antifungal agent. An applicator tip is secured in the opening so that when the first and second ampoules are broken, the first and second components mix to form the mixture and the mixture can egress from the application tip. 1. An applicator for preparing a mixture at a point of use comprising:a housing defining an interior and an opening;first and second containers contained in the interior, wherein the first container contains a first component and the second container contains a second component; andan applicator tip secured in the opening so that when the first and second components are mixed to form the mixture and the mixture can egress from the application tip; andthe component in the first container contains precursors which form a metal oxide and polymer hybridized matrix for controlled delivery of one or more antifungal agent; andthe component in the second container contains the one or more antifungal and/or antimicrobial agent.2. The applicator as recited in claim 1 , wherein the chemistry in the first container forms a matrix of at least one metal oxide consisting of titanium oxide or zirconium oxide or niobium oxide or tantalum oxide or a mixture of these oxides.3. The applicator as recited in claim 1 , wherein the chemistry in the second container contains at least one metal claim 1 , metal oxide claim 1 , metal salt or metal ester of silver claim 1 , vanadium claim 1 , zinc or copper or a mixture of these metals or oxides.4. The applicator as recited in claim 1 , wherein the metal or metal oxide from the second container becomes trapped within the matrix formed by the chemistry in the first container.5. The applicator as recited in claim 1 , where in the ...

Polymer/Copper Combination for Targeted Cancer Therapy

Polymer/copper combination that can selectively target and kill cancer cells are described. Materials can include the reaction product of a biocompatible hydrophilic polymer and pyridine-2-thiol containing monomer. The copolymer reaction product can include pyridine-2-thiol side groups pendant to the backbone via a disulfide linkage. The hydrophilic component can form the polymer backbone and/or can form hydrophilic pendant groups off of the backbone. Copper ions can be associated with the copolymer. 1. A polymer/copper combination comprising a biocompatible copolymer , the biocompatible copolymer including pyridine-2-thiol groups pendant to a backbone of the copolymer via a disulfide linkage , the biocompatible copolymer comprising a hydrophilic component , the polymer/copper combination further comprising copper ions2. The polymer/copper combination of claim 1 , wherein the polymer/copper combination is in the form of a particle claim 1 , the hydrophilic component of the combination being primarily on an exterior surface of the particle.3. The polymer/copper combination of claim 1 , the hydrophilic component further comprising hydrophilic groups pendant to the polymer backbone.4. The polymer/copper combination of claim 3 , wherein the pendant hydrophilic groups comprise poly(ethylene glycol).5. The polymer/copper combination of claim 4 , wherein the pendant hydrophilic groups comprise poly(ethylene glycol)methacrylate.6. The polymer/copper combination of claim 1 , wherein the hydrophilic component comprises poly(ethylene glycol) claim 1 , poly(N-isopropylacrylamide) (polyNIPAAm) claim 1 , poly(N-(2-hydroxypropyl)methacrylamide) (polyHPMA) claim 1 , poly(acrylic acid) (PAAc) claim 1 , poly(DL-lactic acid-co-glycolic acid) PLGA claim 1 , or poly(L-histidine).7. The polymer/copper combination of claim 1 , wherein the pyridine-2-thiol groups comprise (pyridine-2-thiol)ethyl acrylate claim 1 , (pyridine-2-thiol)ethyl methacrylate claim 1 , ethyl(2-(pyridin-2- ...

3D-PRINTING OF ULTRA-HIGH REFRACTIVE INDEX POLYMERS

Sulfur copolymers having high sulfur content for use as raw materials in 3D printing. The sulfur copolymers are prepared by melting and copolymerizing one or more comonomers with cyclic selenium sulfide, elemental sulfur, elemental selenium, or a combination thereof. Optical substrates, such as films and lenses, are constructed from the sulfur copolymer via 3D printing and are substantially transparent in the visible and infrared spectrum. The optical substrates can have refractive indices of about 1.75-2.6 at a wavelength in a range of about 500 nm to about 8 μm. 1. A method of producing a substrate using 3D printing , comprising: i. one or more chalcogenic monomers at a level of at least 50 wt % of the sulfur copolymer; and', 'ii. one or more comonomers each selected from a group consisting of amine comonomers, thiol comonomers, sulfide comonomers, alkynylly unsaturated comonomers, epoxide comonomers, nitrone comonomers, aldehyde comonomers, ketone comonomers, thiirane comonomers, ethylenically unsaturated comonomers, styrenic comonomers, vinylic comonomers, methacrylate comonomers, acrylonitrile comonomers, allylic monomers, acrylate monomers, vinylpyridine monomers, isobutylene monomers, maleimide monomers, norbornene monomers, monomers having at least one vinyl ether moiety, and monomers having at least one isopropenyl moiety, at a level in the range of about 5-50 wt % of the sulfur copolymer;, 'a. providing a print material comprising a sulfur copolymer comprisingb. introducing said print material into a 3D printer; andc. dispensing said print material by successively applying layers of said print material to form the substrate;wherein the substrate produced from the print material has a refractive index of about 1.75-2.6 at a wavelength in a range of about 500 nm to about 8 μm.2. The method of claim 1 , wherein the chalcogenic monomers are selected from a group consisting of elemental sulfur claim 1 , a liquid polysulfide claim 1 , cyclic selenium sulfide and ...

A SULFONATED POLYSTYRENE DERIVATIVE FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF CAT FLU

The present invention relates to a sulfonated polystyrene derivative of formula I for use in the treatment and/or prophylaxis of cat flu, especially infection caused by feline calicivirus or feline herpesvirus, alone or in combination therapy. 112-. (canceled)14. The method of claim 13 , wherein the cat flu is an infection caused by feline calicivirus.15. The method of claim 13 , wherein the cat flu is an infection caused by feline herpesvirus.16. The method of claim 13 , wherein the cat flu is an infection caused by feline herpesvirus type 1 (FHV-1).17. The method of claim 13 , wherein the cat flu of the subject is treated.18. The method of claim 13 , wherein the likelihood of developing cat flue by the subject is reduced.19. The method of claim 13 , wherein the sulfonated polystyrene derivative is in the form of a salt.20. The method of claim 19 , wherein the sulfonated polystyrene derivative is in the form of a sodium salt.21. The method of claim 13 , wherein the sulfonated polystyrene derivative has a molecular weight of at least 1.5 kDa.22. The method of claim 13 , wherein the sulfonated polystyrene derivative has a molecular weight of at least 8 kDa.23. The method of claim 13 , wherein the sulfonated polystyrene derivative has a molecular weight of from 8 kDa to 1200 kDa.24. The method of claim 13 , wherein the sulfonated polystyrene derivative has a molecular weight selected from the group consisting of 8 kDa claim 13 , 19.3 kDa claim 13 , 35 kDa claim 13 , 46 kDa claim 13 , 93.5 kDa claim 13 , 200 kDa claim 13 , 400 kDa claim 13 , 780 kDa and 1200 kDa.25. The method of claim 13 , wherein the sulfonated polystyrene derivative has a molecular weight selected from the group consisting of 93.5 kDa and 780 kDa.26. The method of claim 13 , wherein the sulfonated polystyrene derivative is administered as a combination therapy together with a second agent for the treatment of cat flu.27. The method of claim 26 , wherein the second agent is a nucleoside analogue.28. ...

METHOD FOR PREPARING EYE DROPS OF CYCLOSPORIN A

Eye drops containing cyclosporin A are prepared in the form of an emulsion, a microemulsion, or a lipophilic/hydrophilic micellar solution whose lipophilic, and hence oily, phase contains cyclosporin A. Preparation of the eye drops begins by eliminating at least 99 wt % of ethanol contained in an oily solution of cyclosporin A, under a flow of nitrogen under a pressure of 0.5 bar, at a temperature of from 2° C. to 45° C. and for a period of from 0.25 h to 24 h. The concentrate of cyclosporine is then diluted in an aqueous solution. Next, an emulsion, a microemulsion, or a micellar solution being 75% aqueous phase is created by stirring the concentrated cyclosporine A with the aqueous solution to mix them together. The resulting mixture is sterilely packaged as eye drops in packaging that is suitable for ophthalmic use. 1. A method of preparing an eye drop formulation without preservatives , comprising:a) eliminating at least 99 wt % of ethanol contained in an oily solution, said oily solution comprising cyclosporine A, the ethanol, and polyoxyethylene castor oil, under a flow of nitrogen, under a pressure of 0.5 bar, at a temperature of from 2° C. to 45° C., and for a time period of 14 h to 24 h to form a concentrate of cyclosporine A in the oily solution,b) diluting the concentrate of cyclosporine A in the oily solution obtained in step a) in an aqueous solution,c) mix under stirring the concentrated oily solution obtained in step a) with the aqueous solution obtained in step b), at a temperature of between 2° C. and 45° C. for a period of from 0.05 h to 48 h to obtain a micellar solution having colloidal micelles less than 25 nm in size, andd) sterily packaging the micellar solution obtained in step c) for use as the eye drop formulation in packaging that is suitable for ophthalmic use.2. The method of claim 1 , wherein a lubricating and/or wound-healing agent is added to the aqueous solution in step b) claim 1 , before step c).3. The method of claim 2 , wherein ...

MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES

A hydrophilic biocompatible sustained-release material is disclosed. The material comprises amounts of Pluronic F-127, PEG-400, HPMC and water, effective to produce a composition of sufficiently low viscosity at room temperature to be injectable into an internal body cavity via a tube inserted within a urinary catheter. At body temperature, the material exhibits a much higher viscosity and will stably adhere to the internal surface of a body cavity. As the material dissolves, a therapeutic agent incorporated therein is slowly released to the body cavity, while the material itself is excreted from the body. 114.-. (canceled)16. The thermoreversible hydrogel of claim 15 , comprising:between 0.1% and 0.3% HPMC; andbetween 0.4 and 1.8% PEG-400.17. A thermoreversible hydrogel claim 15 , comprising:between 23% and 27% (w/w) of an ethylene oxide/propylene oxide triblock copolymer characterized by a general formula E101 P56 E101;between 0.1% and 0.2% HPMC;between 0.5% and 1% PEG-400; and the balance water.18. The thermoreversible hydrogel of claim 15 , further comprising at least one component selected from the group consisting of:adhesive and thickening compounds;at least one bonding agents selected from the group consisting of polycarbophil, cellulose, microcrystalline cellulose, cellulose derivatives, low substituted hydroxypropylcellulose (L-HPC), dicalcium phosphate, lactose, PVP and sucrose, ethylcellulose, hydroxypropymethylcellulose acetate succinate (HPMCAS), PVP, vinylpyrrolidone/vinyl acetate copolymer, polyethylene glycol, polyethylene oxide, polymethacrylates, polyvinyl alcohols (PVA), partially hydrolysed polyvinyl acetate (PVAc), polysaccharides, fats and fatty acid derivatives and any combination thereof pH-modifying substances;at least one diffusion coating selected from the group consisting of ethylcelluloses and polymethacrylates, cellulose acetate, cellulose acetate butyrate and any combination thereof,plasticizers;at least one substance selected from ...

CONTROLLABLE SELF-ANNEALING MICROGEL PARTICLES FOR BIOMEDICAL APPLICATIONS

A microporous gel system for certain applications, including biomedical applications, includes an aqueous solution containing plurality of microgel particles including a biodegradable crosslinker. In some aspects, the microgel particles act as gel building blocks that anneal to one another to form a covalently-stabilized scaffold of microgel particles having interstitial spaces therein. In certain aspects, annealing of the microgel particles occurs after exposure to an annealing agent that is endogenously present or exogenously added. In some embodiments, annealing of the microgel particles requires the presence of an initiator such as exposure to light. In particular embodiments, the chemical and physical properties of the gel building blocks can be controlled to allow downstream control of the resulting assembled scaffold. In one or more embodiments, cells are able to quickly infiltrate the interstitial spaces of the assembled scaffold. 166-. (canceled)67. A method of delivering to living mammalian tissue a covalently-stabilized porous scaffold of spherical microgel particles , the method comprising: (i) a cross-linked poly(ethylene glycol) (PEG) backbone polymer cross-linked with a matrix metalloprotease (MMP)-degradable crosslinker; and', '(ii) an annealing component comprising K-peptides and Q-peptides; and, '(a) delivering to the living mammalian tissue a plurality of flowable, spherical microgel particles, wherein the plurality of flowable, spherical microgel particles comprises(b) following delivery in (a), exposing the plurality of flowable, spherical microgel particles to an annealing agent comprising Factor XIIIa that links the plurality of flowable, spherical microgel particles together in a covalent annealing reaction between the K-peptides and the Q-peptides at points of physical contact between adjacent spherical microgel particles to form the covalently-stabilized porous scaffold, wherein the covalently-stabilized porous scaffold comprises pores with ...

SURFACE TREATMENT OF CONTACT LENS AND TREATMENT OF OCULAR DISCOMFORT BY WATER SOLUBLE POLYMERS AND LIPIDS/LIPOSOMES

Formulations (e.g., solutions) comprising one or more water-soluble polymer(s), liposomes, and an aqueous carrier, are provided. The provided solutions are useful for rinsing, and/or immersing therein, a contact lens and/or in the treatment of ocular discomfort, for example, an ocular discomfort associated with a contact lens. Also provided are kits comprising the solution and a contact lens; articles-of-manufacturing comprising the solution and configured for dispending the solution; and methods utilizing the solution. 1. A solution comprising at least one water-soluble polymer , liposomes , and an aqueous carrier , the solution being for use in rinsing , and/or immersing therein , a contact lens.2. A solution comprising at least one water-soluble polymer , liposomes , and an aqueous carrier , the solution being for use in the treatment of ocular discomfort.3. (canceled)4. The solution of claim 1 , wherein said contact lens comprises a hydrogel surface.57-. (canceled)8. The solution of claim 1 , wherein said at least one water-soluble polymer comprises a non-ionic polymer.9. (canceled)10. The solution of claim 1 , wherein said at least one water-soluble polymer comprises an ionic polymer.1113-. (canceled)14. The solution of claim 10 , wherein said liposomes are characterized by a surface charge having a sign opposite a sign of a net charge of said ionic polymer.1517-. (canceled)18. The solution of claim 1 , wherein a concentration of phospholipids of said liposomes in the solution is in a range of from 0.5 mM to 500 mM.1921-. (canceled)22. The solution of claim 1 , wherein a viscosity of the solution is no more than 1000 cP.23. The solution of claim 1 , wherein said carrier is an ophthalmically acceptable carrier.24. An article-of-manufacturing comprising the solution of packaged in a container claim 1 , the container being configured for dispensing the solution.25. (canceled)26. A kit comprising at least one contact lens and the solution of .2729-. (canceled)30. ...

EYE-INJECTABLE POLYMERIC NANOPARTICLES AND METHOD OF USE THEREFOR

The present invention refers to a method for treating visual deficits comprising at least one step of injecting in the eye of a subject in need thereof a therapeutically effective amount of photoactive nanoparticles (NPs) or a composition comprising said photoactive nanoparticles (NPs). 1. A method for treating a visual deficit of at least one eye of a subject in need thereof , comprising at least one step of injecting in the eye of said subject a therapeutically effective amount of photoactive nanoparticles (NPs).2. A method for improving the spatial resolution of at least one eye of a subject in need thereof , comprising at least one step of injecting in the eye of said subject a therapeutically effective amount of photoactive nanoparticles (NPs).3. The method according to claim 1 , wherein the NPs are an aqueous dispersion of NPs.4. The method according to claim 1 , wherein the NPs comprise poly-(3-hexylthiophene).5. The method according to claim 1 , wherein the NPs have a diameter ranging from 50 to 450 nm.6. The method according to claim 1 , wherein the NPs have a polydispersity index (PDI) comprised between 0.008 and 0.05.7. The method according to claim 1 , wherein the NPs have a Z-potential value less or equal to −30 mV.8. The method according to claim 1 , wherein the NPs absorb the wavelength of visible light.9. The method according to claim 1 , wherein the NPs absorb the wavelength of the light ranging from 495 to 620 nm.10. The method according to claim 1 , wherein said NPs are administered intraorbitally by injection into a blood vessel that supplies blood to the eye.11. The method according to claim 1 , wherein said NPs are administered intraorbitally into the macula by first penetrating the sclera.12. The method according to claim 1 , wherein said NPs are administered intraorbitally by microinjection into a subretinal space.13. The method according to claim 1 , wherein said NPs are administered by microinjection into the subretinal space.14. The method ...

ANTIFUNGAL COMPOSITIONS FOR THE TREATMENT OF SKIN AND NAILS

Improvements in or relating to manually operated dispense heads for fluid containers 1. A composition for treating an ungual infection , the composition comprising:(a) an iodophor; and(b) dimethylsulfoxide (DMSO);wherein the composition is capable of penetrating the unguis to treat the infection.2. A composition for treating an ungual infection , the composition comprising:(a) elemental iodine; and(b) dimethylsulfoxide (DMSO);wherein the composition is capable of penetrating the unguis to treat the infection.3. The composition of claim 1 , wherein the iodophor is selected from the group consisting of povidone iodine (PVP-I) claim 1 , iodine tincture claim 1 , Lugol's solution claim 1 , potassium iodide claim 1 , and sodium iodide.4. The composition of claim 3 , where in the iodophor is PVP-I.5. The composition of claim 1 , wherein the composition is substantially anhydrous.6. The composition of claim 1 , wherein the composition is anhydrous.7. The composition of claim 3 , wherein PVP-I is present at about 0.01% to about 10% (w/w).8. The composition of claim 3 , wherein PVP-I is present in a range selected from the group consisting of about 0.05% to about 10% claim 3 , about 0.1% to about 5% claim 3 , about 0.2% to about 2.5% claim 3 , and about 0.5% to about 1% (w/w).9. The composition of claim 3 , wherein PVP-I is present in a range selected from the group consisting of about 0.1% claim 3 , about 0.2% claim 3 , about 0.3% claim 3 , about 0.4% claim 3 , about 0.5% claim 3 , about 1.0% claim 3 , about 1.25% claim 3 , about 1.5% claim 3 , about 2.0% claim 3 , about 2.5% claim 3 , and about 5% (w/w).10. The composition of claim 3 , wherein PVP-I is present at about 1% (w/w).11. The composition of claim 1 , further comprising at least one naturopathic substance.12. The composition of claim 1 , further comprising at least one substance selected from the group consisting of Punica Granatum Extract claim 1 , Camellia Sinensis Leaf Extract claim 1 , Ascorbic Acid claim 1 , ...

COMPOSITION USING CROSS-LINKED HYALURONIC ACID FOR TOPICAL COSMETIC AND THERAPEUTIC APPLICATIONS

Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin. 1. A topical composition comprising: a polysaccharide gel matrix; and a substance , alone , or in combination with , an effective amount of a therapeutic agent deliverable to a skin surface , wherein the therapeutic agent is a salt , a solvate , a prodrug , or a derivative of the therapeutic agent , and wherein the substance , alone or in combination , is entrapped within the matrix.2. A composition according to claim 1 , wherein the polysaccharide is a cross-linked polymer of hyaluronic acid claim 1 , a salt or a derivative of the polymer.3. A composition according to claim 2 , wherein the polymer is in an equilibrium form and is hylan B.4. A topical composition according to claim 2 , wherein the polymer is in a non-equilibrium form and is hylan B.5. A composition according to claim 1 , wherein the substance is a hydrophilic organic ingredient.6. A composition according to claim 5 , wherein the hydrophilic organic ingredient is an α- claim 5 , β- claim 5 , γ- or δ-hydroxy acid claim 5 , an α-amino acid claim 5 , a β-amino acid claim 5 , a γ-amino acid claim 5 , a δ-amino acid claim 5 , a glycerin claim 5 , a vitamin claim 5 , a vitamin derivative claim 5 , a sugar claim 5 , an essential oil claim 5 , a water-soluble oil claim 5 , a fragrance claim 5 , a natural polymer claim 5 , a synthetic polymer claim 5 , a cross-linked natural polymer claim 5 , a cross linked synthetic polymer claim 5 , a peptide claim 5 , a protein claim 5 , a polysaccharide or a nucleic acid.7. A composition according to wherein the hydrophilic organic ...

COMPOSITION USING CROSS-LINKED HYALURONIC ACID FOR TOPICAL COSMETIC AND THERAPEUTIC APPLICATIONS

Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin. 1. A topical composition comprising: a polysaccharide gel matrix; and a substance , alone , or in combination with , an effective amount of a therapeutic agent deliverable to a skin surface , wherein the therapeutic agent is a salt , a solvate , a prodrug , or a derivative of the therapeutic agent , and wherein the substance , alone or in combination , is entrapped within the matrix.2. A composition according to claim 1 , wherein the polysaccharide is a cross-linked polymer of hyaluronic acid claim 1 , a salt or a derivative of the polymer.3. A composition according to claim 2 , wherein the polymer is in an equilibrium form and is hylan B.4. A topical composition according to claim 2 , wherein the polymer is in a non-equilibrium form and is hylan B.5. A composition according to claim 1 , wherein the substance is a hydrophilic organic ingredient.6. A composition according to claim 5 , wherein the hydrophilic organic ingredient is an α- claim 5 , β- claim 5 , γ- or δ-hydroxy acid claim 5 , an α-amino acid claim 5 , a β-amino acid claim 5 , a γ-amino acid claim 5 , a δ-amino acid claim 5 , a glycerin claim 5 , a vitamin claim 5 , a vitamin derivative claim 5 , a sugar claim 5 , an essential oil claim 5 , a water-soluble oil claim 5 , a fragrance claim 5 , a natural polymer claim 5 , a synthetic polymer claim 5 , a cross-linked natural polymer claim 5 , a cross linked synthetic polymer claim 5 , a peptide claim 5 , a protein claim 5 , a polysaccharide or a nucleic acid.7. A composition according to wherein the hydrophilic organic ...

Multi-Vinylsulfone Containing Molecule

A multi-vinylsulfone containing molecule is described herein. The multi-vinylsulfone containing molecule can be formed by dissolving a water soluble polymer containing a hydroxyl group in an aqueous solution to form a polymer solution; adding a molecule containing two vinylsulfone groups to the polymer solution; and forming a modified polymer by controlling a number of the vinylsulfone groups that are added to the polymer. A hydrogel is also described herein that can include the multi-vinylsulfone containing molecule and a multi-thiol containing molecule. The hydrogel can be formed from an aqueous solution that includes the multi-vinylsulfone containing molecule and the multi-thiol containing molecule by undergoing gelatation upon delivery to a site in the body. Also described is a drug delivery system that employs the hydrogel. 2. The drug delivery system of claim 1 , wherein the aqueous solution undergoes the gelatation when the multi-vinylsulfone containing molecule forms a covalent bond with the multi-thiol containing molecule.3. The drug delivery system of claim 2 , wherein the therapeutic molecule is encapsulated within a network formed by the multi-vinylsulfone containing molecule and the multi-thiol containing molecule.4. The drug delivery system of claim 1 , wherein the therapeutic agent is a biomacromolecule or a particle encapsulating a drug molecule.5. The drug delivery system of claim 1 , wherein the drug delivery system is administered by an injection to a surface of the body or to an interior of the body.6. The drug delivery system of claim 1 , wherein the drug delivery system is administered to the body by an intravitreal injection claim 1 , a peribulbar injection claim 1 , or a subtenon injection.7. The drug delivery system of claim 1 , wherein the multi-vinylsulfone containing molecule is a polymer.8. The drug delivery system of claim 7 , wherein the polymer is derived from a hydroxyl containing polymer.9. The drug delivery system of claim 1 , ...

FORMULATIONS OF A COMPOUND MODULATING KINASES

Provided are solid dispersions of Compound I having the formula: 2. The solid dispersion of claim 1 , wherein Compound I is molecularly dispersed within a polymer matrix formed by hydroxypropylmethyl cellulose acetate succinate (HMPCAS) in its solid state.3. The solid dispersion according to claim 2 , wherein the HMPCAS is HMPCAS-LF claim 2 , HMPCAS-MF claim 2 , HMPCAS-HF claim 2 , HMPCAS-LG claim 2 , HMPCAS-MG claim 2 , or HMPCAS-HG.4. The solid dispersion according to claim 2 , wherein the HMPCAS is HMPCAS-HG.5. The solid dispersion according to claim 2 , wherein the weight ratio of Compound I to HMPCAS within the solid dispersion ranges from about 1:1 to about 1:4.6. The solid dispersion according to claim 2 , wherein the weight ratio of Compound I to HMPCAS within the solid dispersion ranges from about 1:2.5 to about 1:3.5.7. The solid dispersion according to claim 2 , wherein the weight ratio of Compound I to HMPCAS within the solid dispersion ranges from about 1:2.6 to about 1:2.9.8. The solid dispersion according to claim 2 , further comprising one or more surfactants.9. The solid dispersion according to claim 8 , wherein the one or more surfactants is sodium lauryl sulfate.10. The solid dispersion according to claim 8 , wherein Compound I ranges from about 15% w/w to about 35% w/w; HMPCAS ranges from about 50% w/w to about 85% w/w; and the one or more surfactants range from about 1% w/w to about 10% w/w.11. The solid dispersion according to claim 8 , wherein Compound I ranges from about 20% w/w to about 30% w/w; HMPCAS ranges from about 60% w/w to about 80% w/w; and the one or more surfactants range from about 3% w/w to about 7% w/w.12. The solid dispersion according to claim 8 , wherein Compound I ranges from about 22% w/w to about 28% w/w; HMPCAS ranges from about 65% w/w to about 75% w/w; and the one or more surfactants range from about 4% w/w to about 6% w/w.13. The solid dispersion according to claim 8 , wherein Compound I is about 25% w/w; HMPCAS is ...

METHOD FOR PREPARATION OF POLY(ALPHA-LIPOIC ACID) POLYMERS

A method for the polymerization of α-lipoic acid and α-lipoic acid derivatives includes preparing an α-lipoic formulation, exposing the α-lipoic formulation to an aqueous phase and a gaseous phase at a gas/water interface, and allowing the α-lipoic formulation to polymerize at the gas/water interface to form a poly(α-lipoic acid) polymer. The α-lipoic formulation can be an α-lipoic solution of an α-lipoic solute and an organic solvent miscible with water, and can also be an α-lipoic acid or oligomer or polymer thereof in liquid (typically melt) form. 1. A method for the polymerization of α-lipoic acid and α-lipoic acid derivatives , the method comprising: (1) an α-lipoic solution of (a) an α-lipoic solute selected from the group consisting of α-lipoic acids, α-lipoic acid based-derivatives, and combinations thereof and (b) an organic solvent miscible with water, and', '(2) an α-lipoic liquid of α-lipoic acids, α-lipoic acid based-derivatives, and combinations thereof;, 'preparing an α-lipoic formulation selected from the group consisting ofexposing said α-lipoic formulation to an aqueous phase and a gaseous phase at a gas/water interface; andallowing the α-lipoic formulation to polymerize at the gas/water interface to form a poly(α-lipoic acid) polymer.2. The method of claim 1 , wherein said α-lipoic formulation is an α-lipoic solution claim 1 , and said organic solvent is selected from ethanol claim 1 , isopropanol claim 1 , methanol claim 1 , acetone claim 1 , glycerin claim 1 , propylene glycol claim 1 , tetraethylene glycol claim 1 , dioxane claim 1 , dimethylsulfoxide and tetrahydrofuran.3. The method of claim 1 , wherein said α-lipoic formulation is an α-lipoic liquid and further includes oligomers or polymers of α-lipoic acid or α-lipoic acid-containing compounds or both.4. The method of claim 3 , wherein the α-lipoic liquid is liquid due to being heated.5. The method of claim 1 , wherein the α-lipoic formulation includes an ester of α-lipoic acid.6. The ...

METHODS AND COMPOSITIONS FOR SELECTIVELY REMOVING POTASSIUM ION FROM THE GASTROINTESTINAL TRACT OF A MAMMAL

The present invention provides methods and compositions for the treatment of ion imbalances using core-shell composites and compositions comprising such core-shell composites. In particular, the invention provides core-shell particles and compositions comprising potassium binding polymers, and core-shell particles and compositions comprising sodium binding polymers, and in each case, pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are also disclosed. The compositions and methods of the invention offer improved approaches for treatment of hyperkalemia and other indications related to potassium ion homeostasis, and for treatment of hypertension and other indicates related to sodium ion homeostasis. 138.-. (canceled)40. The pharmaceutical composition of claim 39 , wherein Rand Rare independently hydrogen or alkyl.41. The pharmaceutical composition of claim 39 , wherein Rand Rare hydrogen.44. The pharmaceutical composition of claim 43 , wherein m is 1 to 10.47. The pharmaceutical composition of claim 46 , wherein z is 2.48. The pharmaceutical composition of claim 47 , wherein Rand Rare independently hydrogen or C-Calkyl;49. The pharmaceutical composition of claim 47 , wherein Rand Rare hydrogen.50. The pharmaceutical composition of claim 49 , wherein Ris —(CH)—Ar—(R).51. The pharmaceutical composition of claim 50 , wherein m is 1 to 3.52. The pharmaceutical composition of claim 50 , wherein Ar is phenyl.53. The pharmaceutical composition of claim 51 , wherein Ar is phenyl.54. The pharmaceutical composition of claim 52 , wherein t is 1.55. The pharmaceutical composition of claim 53 , wherein t is 1.56. The pharmaceutical composition of claim 54 , wherein Ris Cto Calkyl.57. The pharmaceutical composition of claim 55 , wherein Ris Cto Calkyl.58. The pharmaceutical composition of claim 46 , wherein z is 3. This application is a continuation of U.S. patent application Ser. No. ...

PHARMACEUTICAL COMPOSITIONS COMPRISING IODINE AND STEROID AND USES THEREOF FOR SINUS DISEASES

The present invention provides pharmaceutical compositions comprising an iodine-containing compound and a steroid, useful for treating a clinical symptom in a patient's airway (e.g., nose, lung, and sinus), as well as methods for using the same. 1. A pharmaceutical composition for treating a sinus symptom of a patient comprising an iodine-containing compound and a steroid , wherein the steroid comprises fluticasone or budesonide , or a salt or ester thereof.2. The pharmaceutical composition of claim 1 , wherein the iodine-containing compound is an iodophor comprising iodine complexed with a solubilizing agent.3. The pharmaceutical composition of claim 2 , wherein the solubilizing agent comprises an organic polymer claim 2 , an alcohol claim 2 , a polyl claim 2 , a surfactant claim 2 , a surface active anion claim 2 , a cation claim 2 , or a detergent.4. The pharmaceutical composition of claim 2 , wherein the iodine-containing compound comprises povidone-iodine.5. The pharmaceutical composition of claim 4 , wherein the concentration of the povidone-iodine in a fully constituted aqueous solution ranges from about 0.01% to about 10% by weight/weight or weight/volume percentage claim 4 , from about 0.1% to about 2.5% by weight/weight or weight/volume percentage claim 4 , from about 0.15% to about 1.5% by weight/weight or weight/volume percentage claim 4 , from about 0.2% to about 1.0% by weight/weight or weight/volume percentage claim 4 , or about 0.2% by weight/weight or weight/volume percentage.6. (canceled)7. The pharmaceutical composition of claim 1 , further comprising a tonicity agent.8. The pharmaceutical composition of claim 7 , wherein the tonicity agent comprises NaCl claim 7 , NaHCO claim 7 , or HCl.9. The pharmaceutical composition of claim 1 , further comprising a surfactant claim 1 , a viscosity increasing agent claim 1 , a bioadhesive agent claim 1 , or a cooling agent.10. The pharmaceutical composition of claim 9 , wherein the surfactant comprises ...

COMPOSITIONS USING CROSS-LINKED HYALURONIC ACID FOR TOPICAL COSMETIC AND THERAPEUTIC APPLICATIONS

Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin. 120-. (canceled)21. A topical composition comprising: hylan B and an active ingredient , the active ingredient not including water or buffer , wherein hylan B in a non-equilibrium form is loaded by swelling with the active ingredient , thereby the active ingredient becomes entrapped within the hylan B gel matrix.22. The composition according to claim 21 , wherein the active ingredient is a hydrophilic organic ingredient.23. The composition according to claim 22 , wherein the hydrophilic organic ingredient is an α- claim 22 , β- claim 22 , γ- claim 22 , or δ-hydroxy acid claim 22 , an α-amino acid claim 22 , a β-amino acid claim 22 , a γ-amino acid claim 22 , δ-amino acid claim 22 , a glycerin claim 22 , a vitamin claim 22 , a vitamin derivative claim 22 , a sugar claim 22 , an essential oil claim 22 , a water-soluble oil claim 22 , a fragrance claim 22 , a natural polymer claim 22 , a synthetic polymer claim 22 , a cross-linked natural polymer claim 22 , a cross linked synthetic polymer claim 22 , a peptide claim 22 , a protein claim 22 , a polysaccharide or a nucleic acid.24. The composition according to claim 23 , wherein the hydrophilic organic ingredient is an α-hydroxy acid.25. The composition according to claim 21 , wherein the active ingredient is a hydrophobic organic ingredient.26. The composition according to claim 25 , wherein the hydrophobic organic ingredient is a petrolatum claim 25 , a fatty acid claim 25 , a fatty alcohol claim 25 , an oil claim 25 , a lipid or a silicone.27. The composition according to claim ...

bFGF-POLYMER CONJUGATES, METHODS FOR MAKING THE SAME AND APPLICATIONS THEREOF

A heparin mimicking polymer, its conjugate with bFGF, and method of making and using the same are disclosed. In particular, described herein are conjugates of biologic agents (e.g., bFGF) and heparin mimicking polymers having superior stability while retaining full native activity after a variety of stressors. 1. A heparin mimicking polymer , comprising a reactive group that reacts with a moiety in a target protein causing a covalent attachment of the heparin mimicking polymer to the target protein , wherein the reactive group is capable of reacting with the moiety in the target protein selected from the group consisting of a free thiol group , an amine group , an aldehyde group , a carboxyl group , a hydroxyl group , a ketone group , an oxo group , an azide group , an alkyne group , and a combination thereof.2. The heparin mimicking polymer of claim 1 , wherein the reactive group is capable of reacting with the moiety in the target protein which is present naturally in the target protein or added by chemical or biological modification.3. The heparin mimicking polymer of claim 1 , wherein the reactive group is selected from the group consisting of activated disulfides claim 1 , pyridyl disulfide claim 1 , 5-thio-2-nitrobenzoic acid claim 1 , disulfide reductants. Michael acceptors claim 1 , maleimides claim 1 , maleimide derivatives claim 1 , dihalomaleimides claim 1 , vinyl groups claim 1 , vinyl sulfones claim 1 , acryloyl derivatives claim 1 , haloacetyl claim 1 , alkyl halide derivatives claim 1 , aziridines claim 1 , arylating agents claim 1 , isothiocyanates claim 1 , isocyanates claim 1 , acryl azides claim 1 , activated esters claim 1 , N-hydroxysuccinimide esters claim 1 , para-nitrophenyl esters claim 1 , sulfonyl chlorides claim 1 , aldehydes and glyoxals (with or without reductive amination) claim 1 , epoxides (also called oxiranes) claim 1 , carbonates claim 1 , arylating agents claim 1 , imidoesters claim 1 , carbodiirnides claim 1 , anhydrides claim 1 ...

TRANSMISSION PREVENTION OF VIRUSES WITH APPLICATION OF ANTISEPTIC COMPOSITION

Aspects of the present disclosure relate to a method of preventing transmission of an enveloped RNA virus. The method includes applying to a mucosal tissue of a first mammalian subject not substantially colonized by the enveloped RNA virus an effective amount of an antiseptic composition or a pharmaceutically acceptable salt thereof according to a treatment plan. The first mammalian subject not substantially colonized by the enveloped RNA virus interacts with a second mammalian subject colonized by the enveloped RNA virus at a first viral load, the first mammalian subject has a second viral load based on the interaction, the second viral load is no greater than 0.5 log increase over an initial viral load over a duration of the treatment plan. The mucosal tissue is in the nasopharynx, nasal cavity, or anterior nares of the mammalian subject. The antiseptic composition comprises iodine, iodophor, or combinations thereof. 1. A method of preventing transmission of an enveloped RNA virus , comprising:applying, to a mucosal tissue of a first mammalian subject not substantially colonized by the enveloped RNA virus, an effective amount of an antiseptic composition or a pharmaceutically acceptable salt thereof according to a treatment plan;allowing the first mammalian subject not substantially colonized by the enveloped RNA virus to interact with a second mammalian subject colonized by the enveloped RNA virus at a first viral load, the first mammalian subject has a second viral load based on the interaction;wherein the second viral load is no greater than 0.5 log increase over an initial viral load of the first mammalian subject over a duration of the treatment plan;wherein the mucosal tissue is in a nasopharynx, nasal cavity, or anterior nares of the first mammalian subject;wherein the antiseptic composition comprises iodine, iodophor, or combinations thereof, and a hydroxycarboxylic acid.2. The method of claim 1 , further comprising:applying, to the mucosal tissue of the ...

COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN INFECTIONS

A pharmaceutical composition for treating skin infections is described herein. A method using a pharmaceutical composition for treating skin infections is described herein. A pharmaceutical composition for treating skin infections may comprise, in 100 parts of the composition, 1-99 parts of a pharmaceutically acceptable excipient; 99-1 parts of a keratolytic; 99-1 parts ethyl pyruvate; and 99-1 parts povidone iodine. A method for treating skin infections may comprise topical application of a composition to an infected skin cell for a treatment period. 184-. (canceled)85. A method for treating a skin infection comprising administering to a subject having said skin infection , a therapeutically effective amount of a pharmaceutical composition , said pharmaceutical composition comprising:a. at least about 15 weight % of a keratolytic agent;b. about 10 weight % to about 20 weight % of a molecule comprising a pyruvate group; andc. about 1 or less weight % of a halogen containing moiety.86. The method of claim 85 , wherein said keratolytic agent is salicylic acid claim 85 , pyruvic acid claim 85 , chloroacetic acid claim 85 , trichloroacetic acid claim 85 , menthol claim 85 , acetic acid claim 85 , ascorbic acid claim 85 , pantothenic acid claim 85 , lactic acid claim 85 , a salt of any of the above claim 85 , or any combination thereof.87. The method of claim 85 , wherein said keratolytic agent is salicylic acid claim 85 , ester thereof claim 85 , salt thereof claim 85 , or any combination thereof.88. The method of claim 87 , wherein said pharmaceutical composition comprises about 17 weight % of said keratolytic agent.89. The method of claim 85 , wherein said pharmaceutical composition further comprises an excipient claim 85 , wherein said excipient comprises butylated hydroxy toluene.90. The method of claim 88 , wherein said molecule comprising said pyruvate group is ethyl pyruvate.91. The method of claim 90 , wherein said pharmaceutical composition comprises about 15 ...

PHARMACEUTICAL COMPOSITION CONTAINING CELECOXIB

Disclosed herein is a pharmaceutical composition comprising pharmaceutical formulation of complexed Celecoxib and crystalline Celecoxib to provide fast and long lasting continuous pain management with once a daily dosing. The pharmaceutical composition has improved physicochemical properties that provide faster onset of action for acute pain relief and lower GI related side effects for acute pain relief and lower GI related side effects. 117.-. (canceled)19. The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition comprises 50-200 mg Celecoxib equivalent of the Celecoxib complex.20. The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition comprises 50-400 mg crystalline Celecoxib.21. The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition further comprises 40-20 claim 18 ,000 mg pharmaceutically acceptable excipients.22. The pharmaceutical composition of claim 18 , wherein said crystalline Celecoxib is micronized Celecoxib.23. The pharmaceutical composition of claim 22 , wherein the main particle size of said micronized Celecoxib is in the range of between 3-10 μm.24. The pharmaceutical composition of claim 18 , wherein said pharmaceutical composition is suitable for oral administration.25. The pharmaceutical composition of claim 24 , wherein said pharmaceutical composition is suitable for the preparation of liquid dispersible granule claim 24 , sachet claim 24 , orally disintegrating tablet claim 24 , chewing tablet claim 24 , tablet for solution claim 24 , tablet for suspension and immediate release tablet dosage forms.26. The pharmaceutical composition of claim 25 , wherein said pharmaceutical composition comprises liquid dispersible granules of the Celecoxib complex and crystalline Celecoxib.27. The pharmaceutical composition of claim 18 , wherein the Celecoxib complex is prepared by spray drying a solution mixture of 2-propanol and water containing celecoxib claim 18 , the ...

Novel active ingredient in cicatrization and use thereof

The present invention relates to the use of a known compound as an agent for promoting and/or accelerating fibroblast proliferation and/or differentiation and, consequently, cicatrization. This compound is a copolymer of a 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulphonic acid salt and of propenoic acid 2-hydroxyethyl ester. It may be used alone or in combination with other active substances for inducing or accelerating cicatrization. This compound, alone or in combination with another active substance, may be administered directly on the wound and the surrounding area or the mucous membranes, by topical application. It may also be used ex vivo, in particular for generating cells for skin grafts.

Stable Povidone-Iodine Compositions

Disclosed herein are PVP-I-containing compositions, as well as methods of making such compositions, which provide reliable stability for PVP-I preparations, including preparations comprising PVP-I and one or more additional components. 1. A composition suitable for topical administration , comprising povidone-iodine (PVP-I) at a starting concentration between about 0.4% and about 12.5% by weight , wherein after a period of one month after preparing the composition , the PVP-I concentration is at least 98% of the PVP-I starting concentration , and after a period of six months after preparing the composition , the PVP-I concentration is at least 96% of the PVP-I starting concentration.2. A composition suitable for topical administration , comprising a mixture of a) PVP-I at a starting concentration between about 0.4% and about 12.5% by weight; and b) at least one non-steroidal anti-inflammatory (NSAID) selected from the group consisting of amfenac , bromfenac , ketotifen fumarate , diclofenac , diclofenac sodium , flurbiprofen sodium , ketorlac , ketorlac tromethamine , suprofen , celecoxib , naproxen , rofecoxib , and combinations and salts thereof , wherein after a period of one month after mixing the NSAID and PVP-I to form the composition , the PVP-I concentration is at least 98% of the PVP-I starting concentration , and after a period of six months after mixing the NSAID and PVP-I to form the composition , the PVP-I concentration is at least 96% of the PVP-I starting concentration.3. A composition suitable for topical administration , comprising PVP-I at a starting concentration between about 0.001% and about 0.6% by weight , wherein after a period of one month after preparing the composition , the PVP-I concentration is at least 93% of the PVP-I starting concentration , and after a period of six months after preparing the composition , the PVP-I concentration is at least 93% of the PVP-I starting concentration.4. A method of treating a mammal having an otic ...

SURFACE TREATMENT BY WATER-SOLUBLE POLYMERS AND LIPIDS/LIPOSOMES

A method of reducing a friction coefficient of a surface is disclosed herein, comprising attaching a water-soluble polymer to the surface, and contacting the water-soluble polymer with liposomes, thereby coating the surface with an amphiphilic lipid. Further disclosed herein are solutions comprising a water-soluble polymer attachable to the surface, liposomes, and an aqueous carrier, for reducing a friction coefficient of a surface, and methods utilizing same. Articles of manufacture comprising a substrate coated by a water-soluble polymer which is coated by an amphiphilic lipid are also described, as are uses and methods for treating a synovial joint disorder associated with increased articular friction. 1. A method of reducing a friction coefficient of a surface , the method comprising contacting the surface with a solution comprising at least one water-soluble polymer , liposomes , and an aqueous carrier , and modifying the surface so as to obtain a modified surface , wherein said water-soluble polymer and said modified surface are selected such that said water-soluble polymer is attachable to said modified surface.2. The method of claim 1 , wherein a molar percentage of phosphatidylcholine in said liposomes is at least 50%.3. The method of claim 1 , wherein said at least one water-soluble polymer comprises a non-ionic polymer.4. The method of claim 1 , wherein said at least one water-soluble polymer comprises an ionic polymer.5. The method of claim 1 , wherein said at least one water-soluble polymer comprises a biopolymer.6. The method of claim 1 , wherein said water-soluble polymer is selected from the group consisting of a hyaluronic acid claim 1 , a polyvinylpyrrolidone and a polyethylene oxide.7. The method of claim 1 , wherein said surface is a physiological surface claim 1 , and said carrier is a physiologically acceptable carrier.8. The method of claim 7 , wherein said surface is an articular surface of a synovial joint.9. The method of claim 8 , being ...

NITRIC OXIDE-RELEASING DIAZENIUMDIOLATED POLYVINYLPYRROLIDONE-BASED POLYMERS, AND COMPOSITIONS, MEDICAL DEVICES, AND USES THEREOF

Disclosed is a nitric oxide-releasing polyvinylpyrrolidone-based polymer derived from N-vinylpyrrolidone monomer and at least one nitric oxide releasing NO group, in which the NO group is attached to a 2 pyrrolidinone group or a group derived therefrom in the N-vinylpyrrolidone monomer, and the polymer is optionally in combination with a substrate. The NO-releasing polymer can be part of a medical device or pharmaceutical composition and is useful for treating a biological disorder, such as healing a wound, restenosis, and/or promoting angiogenesis. 1. A nitric oxide-releasing polyvinylpyrrolidone-based polymer comprising at least one monomer unit derived from N-vinylpyrrolidone and at least one nitric oxide releasing NOgroup , wherein the NOgroup is attached to a 2-pyrrolidinone group or a group derived from the 2-pyrrolidinone group , or a composite comprising the polymer in combination with a substrate.2. The polymer or composite of claim 1 , wherein the polymer is a copolymer comprising at least one unit derived from N-vinylpyrrolidone.4. The polymer or composite of claim 2 , wherein the copolymer comprises at least one polymerized comonomer selected from the group consisting of acrylonitrile claim 2 , styrene claim 2 , divinylbenzene claim 2 , 4-methylstyrene claim 2 , 4-chloromethylstyrene claim 2 , 4-aminostyrene claim 2 , 4-chlorostyrene claim 2 , 4-bromostyrene claim 2 , 4-vinylphenol claim 2 , 4-vinylpyridine claim 2 , 2-vinylpyridine claim 2 , butadiene claim 2 , 2-chlorobutadiene claim 2 , acrylic acid claim 2 , methacrylic acid claim 2 , methyl methacrylate claim 2 , ethyl methacrylate claim 2 , acrylamide claim 2 , N-methyl acrylamide claim 2 , methylacrylonitrile claim 2 , ethylene claim 2 , propylene claim 2 , isoprene claim 2 , acrolein claim 2 , methacrolein claim 2 , 1-glyceryl methacrylate claim 2 , 2-hydroxyethyl methacrylate claim 2 , 2-hydroxypropyl methacrylate claim 2 , vinyl alcohol claim 2 , allyl alcohol claim 2 , allyl acetate claim 2 , ...

Compositions and methods for treatment of inflammation or infection of the eye

Compositions and methods for preventing, treating or ameliorating a condition or disorder of the eye or area surrounding the eye are disclosed and described.

Xanthohumol-based compositions

This invention relates to xanthohumol-based compositions, yielded in a hot-melt extrusion process (HME) using one or more water-soluble nutritionally and/or cosmetically acceptable thermoplastic polymers, such as selected from hydroxypropylmethyl-cellulose (HPMC), a vinylpyrrolidone-vinyl acetate copolymer, and combinations thereof. The present invention also relates to topical and oral formulations comprising such extruded xanthohumol-based compositions, as well as the use of one or more water-soluble nutritionally and/or cosmetically acceptable thermoplastic polymers in a hot-melt extrusion process of xanthohumol.

SOLID PHARMACEUTICAL COMPOSITION OF CATION EXCHANGE RESIN

The present invention relates to a solid pharmaceutical cation-exchange resin composition allowing the preparation of a stable resin suspension in an aqueous vehicle and the resin being easily resuspended in the case of sediment formation. Said composition comprises hydroxypropyl methylcellulose and pregelatinized starch as functional excipients. The invention also relates to a solid form for oral administration comprising the composition, to the use thereof for the preparation of oral solid forms, and to said composition for use in the treatment of hyperkalaemia. 1. A solid pharmaceutical composition characterised in that it comprises a cation-exchange resin , hydroxypropyl methylcellulose and pregelatinized starch.2. The composition according to claim 1 , characterised in that it further comprises a flavouring agent and optionally a sweetening system.3. The composition according to claim 1 , characterised in that the resin is selected from the group consisting of calcium polystyrene sulphonate and sodium polystyrene sulphonate.4. The composition according to claim 3 , characterised in that the resin is calcium polystyrene sulphonate.5. The composition according to claim 3 , characterised in that the resin is sodium polystyrene sulphonate.6. The composition according to claim 1 , characterised in that the content of cation-exchange resin is comprised between 95.0% and 99.8% by weight with respect to the total weight of the composition.7. The composition according to claim 1 , characterised in that the content of hydroxypropyl methylcellulose is comprised between 0.1% and 2.5% by weight with respect to the total weight of the composition.8. The composition according to claim 1 , characterised in that the content of pregelatinized starch is comprised between 0.1% and 2.5% by weight with respect to the total weight of the composition.9. The composition according to claim 1 , characterised in that it comprises between 95.0% and 97.5% by weight of cation-exchange resin ...

OPHTHALMIC FORMULATIONS

There is provided inter alia a germicidal aqueous formulation, suitable for use in the eye, which has a pH of from 4.0 to 6.5 and which comprises 4.0 to 7.5% w/w of povidone-iodine and a viscosity increasing agent, the formulation buffered with a buffer concentration of 25 mM to 75 mM.

BONE GRAFT MATERIALS CONTAINING CALCIUM PHOSPHATE AND POVIDONE-IODINE

Described herein are materials and methods for reducing the risk of infection at a surgical site performed to restore or repair bone in an animal. Bone graft materials for implantation into a mammal are contemplated containing an antimicrobial agent. In one embodiment the bone graft material comprises both calcium phosphate and povidone-iodine as the antimicrobial agent. In another embodiment the bone graft material further comprises collagen. The bone graft materials are designed so as to maintain the structural integrity and/or handling characteristics of the material upon implantation into a bony site. Various methods for manufacturing the bone graft materials described herein are also contemplated.

COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA

The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance. 2. The crosslinked potassium binding polymer of claim 1 , wherein the ratio of m to n is about 68:1.3. The crosslinked potassium binding polymer of claim 1 , wherein the potassium binding polymer is characterized by a swelling ratio in water of between about 3 grams of water per gram of polymer to about 8 grams of water per gram of polymer.4. The crosslinked potassium binding polymer of claim 1 , wherein the potassium binding polymer is characterized by a swelling ratio in water of between about 3 grams of water per gram of polymer to about 4.5 grams of water per gram of polymer.5. The crosslinked potassium binding polymer of claim 1 , wherein the potassium binding polymer is characterized by a swelling ratio in water of about 3.3 grams of water per gram of polymer.6. The crosslinked potassium binding polymer of claim 1 , wherein the potassium binding polymer is characterized by a swelling ratio in water of about 4.3 grams of water per gram of polymer.7. The crosslinked potassium binding polymer of claim 1 , wherein the potassium binding polymer further comprises substantially spherical particles having a median diameter from about 5 μm to about 130 μm.8. The crosslinked potassium binding polymer of claim 7 , wherein the particles have an average particle size Dv(0.9) between about 80 μm to about 130 μm.9. The crosslinked potassium binding polymer of claim 7 , wherein the particles have an average particle size Dv(0.9) between about 90 μm to about 120 μm.10. The crosslinked potassium binding polymer of claim 7 , wherein the particles have an average particle size Dv(0.9) between about 40 μm to about 70 μm.11. The crosslinked potassium binding polymer of claim 7 , ...

PHARMACEUTICAL COMPOSITIONS FOR TREATING HYPERKALEMIA

The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance. 2. The pharmaceutical composition of claim 1 , wherein the ratio of m to n is about 68:1.3. The pharmaceutical composition of claim 1 , wherein the potassium binding polymer is characterized by a swelling ratio in water of between about 3 grams of water per gram of polymer to about 8 grams of water per gram of polymer.4. The pharmaceutical composition of claim 1 , wherein the potassium binding polymer is characterized by a swelling ratio in water of between about 3 grams of water per gram of polymer to about 4.5 grams of water per gram of polymer.5. The pharmaceutical composition of claim 1 , wherein the potassium binding polymer is characterized by a swelling ratio in water of about 3.3 grams of water per gram of polymer.6. The pharmaceutical composition of claim 1 , wherein the potassium binding polymer is characterized by a swelling ratio in water of about 4.3 grams of water per gram of polymer.7. The pharmaceutical composition of claim 1 , wherein the potassium binding polymer further comprises substantially spherical particles having a median diameter from about 5 μm to about 130 μm.8. The pharmaceutical composition of claim 7 , wherein the particles have an average particle size Dv(0.9) between about 80 μm to about 130 μm.9. The pharmaceutical composition of claim 8 , wherein the particles have an average particle size Dv(0.9) between about 90 μm to about 120 μm.10. The pharmaceutical composition of claim 7 , wherein the particles have an average particle size Dv(0.9) between about 40 μm to about 70 μm.11. The pharmaceutical composition of claim 10 , wherein the particles have an average particle size Dv(0.9) between about 50 μm to about 60 μm.12. The ...

PHARMACEUTICAL COMPOSITIONS FOR TREATING HYPERKALEMIA

The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance. 2. The pharmaceutical composition of claim 1 , wherein the ratio of m to n is about 68:1.3. The pharmaceutical composition of claim 1 , wherein the potassium binding polymer is characterized by a swelling ratio in water of between about 3 grams of water per gram of polymer to about 8 grams of water per gram of polymer.4. The pharmaceutical composition of claim 1 , wherein the potassium binding polymer is characterized by a swelling ratio in water of between about 3 grams of water per gram of polymer to about 4.5 grams of water per gram of polymer.5. The pharmaceutical composition of claim 1 , wherein the potassium binding polymer is characterized by a swelling ratio in water of about 3.3 grams of water per gram of polymer.6. The pharmaceutical composition of claim 1 , wherein the potassium binding polymer is characterized by a swelling ratio in water of about 4.3 grams of water per gram of polymer.7. The pharmaceutical composition of claim 1 , wherein the potassium binding polymer further comprises substantially spherical particles having a median diameter from about 5 μm to about 130 μm.8. The pharmaceutical composition of claim 7 , wherein the particles have an average particle size Dv(0.9) between about 80 μm to about 130 μm.9. The pharmaceutical composition of claim 8 , wherein the particles have an average particle size Dv(0.9) between about 90 μm to about 120 μm.10. The pharmaceutical composition of claim 7 , wherein the particles have an average particle size Dv(0.9) between about 40 μm to about 70 μm.11. The pharmaceutical composition of claim 10 , wherein the particles have an average particle size Dv(0.9) between about 50 μm to about 60 μm.12. The ...

COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA

The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance. 1316-. (canceled)318. The method of claim 317 , wherein the ratio of m to n is 68:1.319324-. (canceled)325. The method of claim 317 , wherein the potassium binding polymer is characterized by a swelling ratio in water of between about 3 grams of water per gram of polymer to about 8 grams of water per gram of polymer.326. The method of claim 317 , wherein the potassium binding polymer is characterized by a swelling ratio in water of between about 3 grams of water per gram of polymer to about 4.5 grams of water per gram of polymer.327. The method of claim 317 , wherein the potassium binding polymer further comprises substantially spherical particles having a median diameter from about 5 μm to about 130 μm.328333-. (canceled)334. The method of claim 327 , wherein ratio of Dv(0.9):Dv(0.5) is about two or less and the ratio of Dv(0.5):Dv(0.1) is about five or less.335. The method of claim 327 , wherein the ratio of Dv(0.9):Dv(0.5) and the ratio of Dv(0.5):Dv(0.1) are each independently about two or less.336. The method of claim 317 , wherein the potassium binding polymer has a potassium exchange capacity from about 1 mEq to about 4 mEq per gram of potassium binding polymer.337. (canceled)338. (canceled)339. The method of claim 317 , wherein the patient is experiencing hyperkalemia.340. The method of claim 317 , wherein the patient is a human.341412-. (canceled)413. The method of claim 317 , wherein the potassium binding polymer is characterized by a swelling ratio in water of about 3.3 grams of water per gram of polymer.414. The method of claim 317 , wherein the potassium binding polymer is characterized by a swelling ratio in water of about 4.3 grams of water per gram ...

ANTISEPTIC COMPOSITIONS AND METHODS

A skin antisepsis composition comprising a vehicle comprising a (C1-4)alcohol and water in a ratio of at least 60:40, a hydroxycarboxylic acid, a cationic film-forming polymer, and at least one antimicrobial agent; and methods of using the composition are provided. 1. An antiseptic composition for use in disinfecting tissue , wherein the antiseptic composition comprises:an antimicrobial agent selected from the group consisting of iodine, an iodophor, and a combination thereof, wherein the antimicrobial agent is present in an amount sufficient to provide an available iodine concentration of at least 0.25 wt-%;a hydroxycarboxylic acid buffer in a molar concentration of at least 0.3 molar; andwater.2. The antiseptic composition for use according to claim 1 , wherein the antiseptic composition further includes one or more nonionic claim 1 , anionic claim 1 , or amphoteric surfactants.3. The antiseptic composition for use according to claim 2 , wherein the surfactant is an anionic or amphoteric surfactant.4. The antiseptic composition for use according to claim 3 , wherein the anionic or amphoteric surfactant is selected from the group consisting of sulfonates claim 3 , sulfates claim 3 , phosphates claim 3 , phosphonates claim 3 , and ammonium sulfonate amphoterics claim 3 , and mixtures thereof.5. The antiseptic composition for use according to claim 4 , wherein the hydroxycarboxylic acid buffer is present in a molar concentration of at least 0.45 molar.6. The antiseptic composition for use according to claim 1 , wherein the antiseptic composition further includes a film-forming polymer.7. The antiseptic composition for use according to claim 6 , wherein the film-forming polymer is cationic.8. The antiseptic composition for use according to wherein the iodophor is povidone-iodine.9. The antiseptic composition for use according to wherein the tissue is skin or mucosal tissue.10. The antiseptic composition for use according to claim 9 , wherein the mucosal tissue is ...

METHOD AND SYSTEM FOR TREATING WOUNDS

A method and a system comprise receiving an amount of a first disinfecting solution on and around a wound. An amount of a second disinfecting solution is received on and around the wound. An amount of a third disinfecting solution is received on and around the wound. An amount of a fourth disinfecting solution is received around the wound. Cold laser emissions are received on and around the wound. Said cold laser emissions comprise at least multiple wavelengths. A sterile gauze bandage and wrap cover the wound. 1. A method comprising the steps of:receiving an amount of a first disinfecting solution on and around a wound;receiving an amount of a second disinfecting solution on and around the wound;receiving an amount of a third disinfecting solution on and around the wound;receiving an amount of a fourth disinfecting solution around the wound;receiving cold laser emissions on and around the wound, said cold laser emissions comprising at least multiple wavelengths; andreceiving a sterile gauze bandage and wrap covering the wound.2. The method as recited in claim 1 , in which said first disinfecting solution comprises medical acidified water.3. The method as recited in claim 1 , in which said second disinfecting solution comprises water claim 1 , citric acid claim 1 , ammonium hydroxide claim 1 , sodium lauryl sulfate claim 1 , and thyme oil.4. The method as recited in claim 1 , in which said third disinfecting solution comprises a tea tree oil.5. The method as recited in claim 1 , in which said fourth disinfecting solution comprises a betadine.6. The method as recited in claim 1 , in which said cold laser emissions further comprises a substantially 660 nanometer wavelength red light claim 1 , a substantially 875 nanometer infrared red light claim 1 , a substantially 905 nanometer super-pulsed light claim 1 , and a static magnetic field of substantially 35 transverse magnetic.7. The method as recited in claim 1 , further comprising the steps of:receiving an amount of ...